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The Western Cape Province of South Africa has a well-established program that monitors 
active combination antiretroviral therapy (cART) against HIV-1. The HIV-1 prevalence rate 
in the Province has increased from 5.0% in 2011 to 18.0% in 2015. South Africa has the 
highest rate of infections worldwide (19.2%). In this study, we analyzed the Protease (PR), 
Reverse Transcriptase (RT) and Intergrase (IN) regions of HIV-1 for diversity and resistance-
associated mutations (RAMs) from samples obtained from the Cape Winelands, West Coast 
and Overberg districts of the Province, where no such study has ever been conducted. 
Samples were received from our diagnostic laboratory for HIV-1 viral load testing, through 
the National Health Laboratory Services (NHLS). Two hundred and five (205) patient 
samples with a viral load of 2000 copies/ml and above were included, based on Gall et al., 
(2012) who showed that a sensitivity of at least 2000 copies/ml is a limit of amplification for 
the SuperScsript ® III one-step RT with Platinum Taq DNA Polymerase kit, used in this 
study. We screened for HIV-1 diversity and RAMs using the pol PR, RT and IN regions with 
a laboratory-based PCR and sequencing protocol. Sequence-specific subtype analyses were 
executed with the REGA HIV subtyping tool 3.0, Recombinant Identification Program (RIP) 
3.0 and subtype classification using evolutionary algorithms (SCUEAL) software. Sequences 
were screened for RAMs using the Stanford University HIV Drug Resistance Database 
(HIVdb) 8.1. We successfully PCR amplified 170 (82.9%) PR and 166 (80.9%) RT 
fragments. For the IN region, only 176 samples had sufficient plasma and RNA left after 
genotyping of the PR and RT regions. For IN we successfully amplified 143 (81.3%) of the 
patient samples. A total of 197 (96.1%) samples could be amplified for at least one of the pol 
regions. Of these, 62 (53.4%) PR, 103 (62.0%) RT and 93 (86.1%) IN sequences were 
obtained, respectively. We could successfully sequence 173 (84.4%) of the samples included. 
HIV-1 subtype C was predominant (n = 144; 93.7%), with 5.3% of other subtypes detected. 
This includes A1 (n = 2; 1.3%), B (n = 4; 2.6%), D (n = 1; 0.7%) and H (n =1; 0.7%). No 
major RAMs were detected against PI and IN inhibitors. Minor RAMs were detected in 4 PR 
(3.7%) and 15 IN (16.1%) sequences analysed. RAMs against RT inhibitors were detected in 
63 (61.7%) of the sequences analyzed. This includes 39 NRTI mutations (36.1%) and 71 
NNRTI mutations (63.5%) identified. As the national cART program continues to expand, 
HIV-1 diversity, viral load monitoring and drug resistance screening remains critical for the 
success of cART outcomes and reducing transmission rates. Our results reflect that subtype C 
is still the driving force of the epidemic in South Africa. However, we cannot ignore the 
potential impact of non-C subtypes. Sequence analyses confirm that the majority of patients 




receiving viral load testing have major RAMs against RT inhibitors used in first line therapy. 
Better surveillance systems for HIV diversity and drug resistance testing are required to 
ensure success of cART. 
 






Die Wes-Kaap Provinsie van Suid-Afrika het 'n goed gevestigde program wat aktief 
kombinasie antiretrovirale terapie (cART) teen MIV-1 monitor. Die MIV-1 voorkomssyfer in 
die Provinsie het toegeneem van 5,0% in 2011 tot 18,0% in 2015. Suid-Afrika het die hoogste 
koers van infeksies wêreldwyd (19,2%). In hierdie studie het ons die Protease (PR), 
Trutranskriptase (RT) en Intergrase (IN) streke van MIV-1 vir diversiteit en weerstand 
geassosieerde mutasies (RAMS) ontleed. Die monsters is verky vanuit die Kaapse Wynland, 
Weskus en Overberg distrikte van die Provinsie, waar geen sodanige studie ooit gedoen is 
nie. Monsters wat getoets was vir MIV-1 viruslading is van ons diagnostiese laboratorium 
seksie deur die NHLS verkry. 205 pasiënt monsters met 'n virale lading van 2000 kopieë / ml 
of meer is in ons studie ingesluit. Ons kriteria is gebaseer op Gall et al., (2012) wat getoon 
het dat 'n sensitiwiteit van ten minste 2000 kopieë / ml 'n beperking is vir amplifisering met 
die SuperScsript ® III een-stap RT met Platinum Taq DNA-polimerase kit, wat in hierdie 
studie gebruik is. Ons ondersoeke is gedoen met ’n laboratorium-gebaseerde PCR en DNS 
volgorde bepalings protokol. MIV-1 subtipe analises is uitgevoer met die volgende aanlyn 
sagteware: REGA 3.0; RIP 3.0 en SCUEAL. Die Stanford Universiteit se MIV weerstand 
aanlyn databasis (HIVdb) 8.1 is gebruik om die voorkomssyfer van RAMs te bepaal. Uit 'n 
versameling van 205 monsters het ons suksesvol 170 (82.9%) PR en 166 (80.9%) RT 
fragmente geamplifiseer. Vir die IN gebied was slegs 176 monsters oor met genoeg plasma 
en RNA vir verdere toetse. Vir die IN gebied kon ons 143 (81.3%) monsters suksesvol 
amplifiseer. Ons kon vir 197 (96.1%) van die monsters ten minste een van die pol streke 
amplifiseer. Hiervan is 62 (53.4%) PR, 103 (62.0%) RT en 93 IN (86.1%) DNS volgordes 
onderskeidelik verkry. Ons kon suksesvol die MIV-1 DNS volgorde bepaal van ten minste 
een pol gebied van 173 (84.4%) van ons totale monsters. MIV-1 subtipe C was oorheersend 
(n = 144; 93,7%), met 5.3% wat as ander subtipes geklasifiseer is. Dit sluit in A1 (n = 2; 
1.3%), B (n = 4; 2.6%), D (n = 1; 0.7%) en H (N = 1; 0.7%). Daar was geen groot RAMs teen 
PR en IN middels nie. Kleiner RAMs is identifiseer in 4 (3.7%) PR en 15 (16.1%) volgordes 
wat ontleed is. RAMs teen RT-middels is opgespoor in 63 (61,7%) van die volgordes ontleed. 
Dit sluit in 39 NRTI mutasies (36,1%) en 71 NNRTI mutasies (63,5%) geïdentifiseer. Soos 
die nasionale cART program uitgebrei word, word MIV-1 diversiteit, viruslading en 
weerstandstoetse al hoe belangriker, veral om die sukses van cART te bepaal. Ons resultate 
toon dat subtipe C steeds die dryfkrag van die epidemie in Suid-Afrika is. Ons kan egter nie 




die potensiële impak van nie-C subtipes ignoreer nie. Volgorde analises bevestig dat die 
meerderheid van die pasiënte wat virale lading toetse ondergaan weerstand het teen RT-
middels wat in die eerste lyn behandeling gebruik word. Beter toesig stelsels is nodig om 
optimale sukses cART te verseker. 
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1. Introduction and literature review 
1.1. Introduction 
The human immunodeficiency virus (HIV) is the causative agent of the Acquired 
Immunodeficiency Syndrome (AIDS) epidemic we currently face (Hatziioannou et al., 2014, 
Sharp & Hahn, 2011). It is estimated that 36.7 million people worldwide are currently living 
with HIV/AIDS (UNAIDS 'Fact Sheet', 2016). Of these, approximately 19.0 million are 
living in Eastern and Southern Africa (Figure 1.1), about 1.1 million deaths were recorded in 
2015 and 2.1 million people were newly infected (UNAIDS gap report, 2016). South Africa 
remains the region that is the most affected by HIV-1, with 7.0 million people living with the 
virus (UNAIDS gap report, 2016). In South Africa, the highest prevalence of HIV/AIDS is 
recorded in Kwazulu-Natal (KZN) Province (40.1%), with the lowest prevalence recorded in 
the Western Cape Province (18.0%) (NDOH, 2014). HIV prevalence in the Western Cape 
Province is significantly lower than the national estimates. However, there is a lack of data 
regarding the HIV-1 diversity and drug resistance, especially in remote communities found 
within the district of the Cape Winelands, the Westcoast and Overberg. The majority of 
research on HIV diversity and drug resistance testing in South Africa has been done in major 
centers, such as Cape Town (Western Cape), Johannesburg (Gauteng) and Durban (Kwazulu-
Natal), where academics have easier access to clinics and patient samples. 
In this study, we investigated the diversity of HIV-1 and drug resistance-associated mutations 
(RAMs) in cohorts from three remote districts of the Western Cape province in South Africa: 
This includes the West Coast with a prevalence of 9.6%, the Overberg region with a 
prevalence of 13.9% and Cape Winelands with a prevalence of 15.0%; which collectively 
accounts for 38.5% of HIV/AIDS prevalence cases in the Western Cape Province (NDOH, 
2014). In the 1980s, HIV-1 subtype B and D viruses were the driving force of the South 
African epidemic (Sher et al., 1989; Engelbrecht et al., 1995; Williamson et al., 1995). 
Currently, the majority of South African individuals are infected with HIV-1 (group M) 
subtype C (Gordon et al., 2003; Jacobs et al., 2009). A relatively small number of Subtype A, 
D, CRF01_AE and other recombinant viruses have also been identified in the country 
(Hemelaar et al., 2006; Bredell et al., 2002; Papathanasopoulos et al., 2010). Among 7.0 
million HIV-1 positive South Africans, only 3.4 million are currently receiving combination 




antiretroviral therapy (cART). The new recommendations state to start cART immediately 
after being diagnosed with HIV-1, regardless of viral load or CD4 cell counts (WHO, 2015). 
The World Health Organization (WHO) cART guidelines recommend the use of a non-
nucleoside reverse transcriptase inhibitor (NNRTI) and two nucleoside reverse transcriptase 
inhibitors (NRTIs) as the first-line cART regimen and two NRTIs, a ritonavir (RTV)-boosted 
protease inhibitors (bPI) as the second line therapy and Integrase strand transfer inhibitor 
(INSTs) as the third line therapy (WHO, 2016). One of the major drawbacks that hampers` 
the efficacy of Highly Active ART (HAART) is the emergence of drug resistance mutations 
conferred in the HIV-1 genome (Hu & Kuritzkes, 2014).  
 
Figure 1.1: Estimated number of people living with HIV/AIDS at the end of 2015. 
Sub-Saharan Africa, Asia and the Pacific are the geographical areas with the largest number of HIV-1 
infections. The continents with the lowest number of infections are the Middle East and North Africa as well as 
in Eastern Europe and Central Asia (UNAIDS, 2015). 
1.2 Literature Review 
A brief literature review relevant to my study is given below. This includes the history of 
HIV, the origin of how HIV was introduced to the human population, the structural genome 
of HIV-1, HIV diversity, the HIV life cycle, the mechanisms by which cART inhibit the viral 
replication and the mechanisms that HIV-1 uses to reduce the susceptibility to cART. 




1.2.1. History of HIV infection 
By the early 1980s, AIDS was established as a new and distinct clinical entity among men 
having sex with men (MSM) in the United States of America (USA), when they presented 
with unusual opportunistic infections, such as pneumonia caused by Pneumocystis carinii, 
which is a rare disease causing lung infections in humans with compromised / downregulated 
immune system. In addition, the occurrence of a rare type of skin cancer caused by Human 
Herpesvirus 8 (HHV 8) referred to as Kaposi’s Sarcoma was also observed in some of the 
homosexual men in the USA (Gottlieb et al., 1981; Friedman-Kien et al., 1981). AIDS cases 
were subsequently observed in other groups of patients presenting with similar symptoms, 
such as intravenous drugs users (IDUs), hemophiliacs and blood transfusion recipients 
(Barre-Sinoussi et al., 1983; Curran et al., 1984). In 1982 various published articles reported 
the emergence of the disease in infants who were born to mothers who were IDUs (MMWR – 
December, 1982b). Molecular epidemiology investigations in Africa reported similar clinical 
symptoms among homosexual men and the heterosexual population of Kinshasa, the capital 
city of the Democratic Republic of Congo (DRC) (Worobey et al., 2008). The first indication 
that a retrovirus is the causative agent of AIDS was discovered by Barré-Sinoussi and 
colleagues in 1983. The virus was isolated from a serum sample and a lymph node biopsy 
specimen collected from a homosexual man who presented with lymphadenopathy syndrome 
(LAS), a disease that affects the lymph node, leading to the name lymphadenopathy virus 
(LAV) (Barré-Sinoussi et al., 1983). In 1984, the virus was independently isolated by Levy 
and co-workers who called it AIDS-associated retrovirus (ARV) (Levy et al., 1984). The 
same virus was investigated by Robert Gallo and his colleagues who hypothesized that a 
variant of the human T-lymphotropic virus (HTLV) might be the causative agent of AIDS 
(Gallo et al., 1984). By 1985 the same virus had three names: LAV, ARV and HTLV-III, 
which all accounted for causing AIDS (Ratner et al., 1985a; 1985b). In order to prevent 
confusion the International Committee on the Taxonomy of viruses proposed to rename the 
AIDS causing virus Human Immunodeficiency Virus (HIV), as it is known today. (Coffin et 
al., 1986a; 1986b). 
1.2.2. Origin of HIV 
From a number of studies focusing on the origin of HIV, many revealed that HIV might have 
originated through cross-species infection (zoonotic transmission) from infected African 
primates to the human population, particularly in West and Central Africa (Apetrei et al., 
2005; Nahmias et al., 1986). This was probably through hunting non-human primates as a 




source of food (bushmeat), trade and keeping  non-human primates as pets (Hahn et al., 2000; 
Sharp et al., 2010; Sharp et al., 2011). Phylogenetic analyses of HIV sequences clearly 
indicate that HIV is derived from simian immunodeficiency viruses (SIVs), commonly found 
in non-human primates. Chimpanzees, Pan troglodytes troglodytes was found to be the 
reservoir for HIV-1 (Gao et al., 1999; Hahn et al., 2000), while the sootey mangabey, 
Cercocebus atys, are the likely reservoir for HIV-2 (Gao et al., 1992; Hahn et al., 2000; 
Hirsch et al., 1989). More evidence that supports the spill-over of the virus into the human 
population is that the non-human primates that have been infected by SIVs are naturally 
resistant to the virus and this virus fails to induce any AIDS- like a disease in natural infected 
non-human primates (Paiardini et al., 2009; Pandrea et al., 2008). This illustrates that the 
virus has evolved with their host for a long period of time and acquired the ability to adapt to 
a host that they infect or with whom they co-exist for commensalism (Rey-Cuille et al., 1998; 
Cichutek & Norley, 1993). Molecular clock and phylogenetic methodology dates the first 
HIV transmission into the human population back to the early 1930s with a ± 20 year 
confidence gap, before anyone becomes aware of the existence of the virus (Hahn et al., 
2000; Korber et al., 2000; Lemey et al., 2003; Lemey et al., 2004; Worobey et al., 2008; 
Wertheim & Worobey, 2009; Silvestri, 2007). 
1.2.3. HIV-1 genome structure 
This thesis focusses on the PR, RT, and IN genes for further characterization of HIV-1 
diversity. The pol gene is routinely sequenced in the clinical use of drug resistance testing 
context. HIV-1 subtypes can be determined based on the pol gene, as the fragment is long 
enough to determine HIV genotypes (Pasquier et al., 2001; Kessler et al., 2001; Yahi et al., 
2001). 
A structure of the HIV-1 genome is presented in Figure 1.2. HIV is a retrovirus, composed of 
double-stranded genomic RNA that is approximately 9kb in size (Zhuang et al., 2002). The 
virus encodes nine open reading frames of which three of these (gag, pol and env) are found 
in all retrovirus (Gallo et al., 1988). The structural components of the virion compose of six 
proteins that form the building block of the viral core and the outer membrane envelope. 
These are the four Gag proteins Capsid (CA), Matrix (MA), Nucleocapsid (NC) and p6, and 
the two Env proteins, Surface (SUsurface or gp120) and Transmembrane (TM or gp41). The 
polymerase gene (pol) encodes three of the major enzymatic components, Protease (PR), 
Reverse Transcriptase (RT) and Integrase (IN) that plays unique roles in other retroviruses.  




HIV encodes at least six additional proteins that are not necessary for HIV replication, but do 
play a role in the viral replication cycle. These proteins are called the accessory proteins and 
regulatory proteins. Three of the accessory proteins, [Virion infectivity factor (Vif), Viral 
protein R (Vpr), and Negative factor (Nef)] are packed in the viral particle core and they play 
a role in increasing production of the HIV proteins. The vif gene increases the production of 
the HIV particle in the peripheral blood lymphocytes (Strebel et al., 1987). Vpr facilitates the 
infection of non-dividing cells by HIV (Heinzinger et al., 1994), while Nef plays a role in 
downmodulation of the CD4 and MHC class I (Schwartz et al., 1996). Two other regulatory 
proteins, Transcriptional transactivator protein (Tat) and Regulator of expression of virion 
proteins (Rev) are essential for regulating the production of HIV in vitro (Kim et al., 1989) 
and the last Viral protein U gene (Vpu), helps in the assembly of the virion indirectly 
(Estrabaud et al., 2007).  
 
Figure 1.2: The HIV-1 genome structure. 
The Structural genes (gag, pol and env) regulatory genes (tat and rev) and accessory genes (nef, vif, vpr and vpu) 
are indicated  in Figure 1.2, as well as the proteins encoded by each genomic region (Source: 
www.hiv.lanl.gov). 
 
1.2.4. HIV diversity  
During this study we investigated the HIV-1 diversity of PR, RT and IN within our  samples. 
Most of the therapeutic inhibitor drugs are designed to target these regions of the HIV-1 
genome to inhibit HIV replication. They have proven to be efficient and successful to control 
viral replication to undetectable levels in the majority of HIV infected patients. The pol 
region is the most conserved part of the HIV-1 genome (Armstrong et al., 2009; Rhee et al., 
2006). However, genetic diversity and HIV-1 resistance pose a major threat to the success of 




therapy. There have been reports where RAMs are subtype- specific (Carr et al., 2006; Taylor 
et al., 2008; Grossman et al., 2004). A study conducted by Grossman et al., 2004, showed 
that the majority of the patients infected with subtype B viruses rarely develop V106→M 
mutations, whereas patients Infectected with subtype C develop RAMs against NNRTIs 
through either V106→M or K103→N mutations.  
A schematic figure of HIV diversity is presented in Figure 1.3, while the global HIV subtype 
distribution is depicted in Figure 1.4. HIV diversity and its complexity in the worldwide 
epidemic is characterized by enormous genetic variation. Several factors contribute to the 
HIV genetic variation. This includes rapid replication of the virus, spontaneous turnover of 
HIV-1 in vivo (Roberts et al., 1988), host selective pressure, the high mutation rate of the RT 
enzyme, which lacks a proofreading function and recombination of strains within infected 
individuals (Roberts et al., 1988; Hodd et al., 1995; Spira et al., 2003; Rambau et al., 2004; 
Perelson et al., 1996). Insertions and deletions in the viral genome are also frequent 
occurrences (Korber et al., 2000). Based on the phylogenetic analyses, HIV-1 strains can be 
classified into four main groups, namely M (major group), O (outlier), N (non-M non-O 
viruses) and the most recently P virus (Plantier et al., 2009). 
Group M viruses account for 52% of the global HIV-1 burden and can be further subdivided 
into discrete subtypes (A-D, F-H, J and K), circulating recombinant forms (CRFs) and many 
unique recombinant forms (URFs) (Hemelaar et al., 2011). HIV-1 subtype B accounts for 
more than 95% of HIV-1 in the USA (Bennett, 2005). From 2004 to 2007, nearly one-half of 
all global infections were caused by subtype C (48%), followed by subtypes A (12%) and B 
(11%), CRF02_AG (8%), CRF01_AE (5%), subtype G (5%), and subtype D (2%) (Hemelaar 
et al., 2011). Subtypes F, H, J and K cause less than 1% of infections worldwide. Other 
recombinant forms (CRFs and URFs) together cause 4% of global infections and combined 
with the burden of CRF02_AG and CRF01_AE infections, 20% of known HIV infections 
worldwide are currently caused by all recombinants (Hemelaar et al., 2011). 





Figure 1.3: HIV-1 Phylogenetic tree derived from nucleotide alignment of genome sequences. 
The different HIV-1 groups indicated, rooted with SIVcpzANT. The group M subtypes (A-D, F-H, and J) are 
shown, while reference sequences for groups N, O and P are also marked (Vallari et al., 2011). 





Figure 1.4: Global distribution of HIV-1 group M-subtypes and recombinant forms. 
Countries are color-coded according to their last reported prevalence (Stack et al., 2010). Pie charts on Figure 
1.4 represent the distribution of HIV-1 subtypes and recombinants over the globe. The colours representing the 
different HIV-1 subtypes and recombinants are indicated in the legend below of the figure.  
1.2.4.1. HIV diversity in South Africa 
By the late 1980s HIV-1 (group M) subtype C was identified among heterosexual individuals 
as the dominant subtype causing  infection (Van Harmelen et al., 1997). Since then, the South 
African epidemic has been dominated by HIV-1 subtype C (Hemelaar et al., 2011).  
Today, the HIV epidemic in South Africa alone has affected more than 7.0 million people 
(UNAIDS gap report, 2016). There is an increasing number of HIV-1 recombinants and non-
C subtypes strains being identified in South Africa (Hemelaar et al., 2006; Bredell et al., 
2002; Papathanasopoulos et al., 2010; Jacobs et al., 2014). In the Westen Cape Province of 
South Africa approximately 1 - 10% HIV-1 infections has been ascribed to non-C strains 
(Engelbrecht et al., 1995; Van Harmelen et al., 1997; Bredell et al., 2002; Jacobs et al., 2009; 
Jacobs et al., 2014; Wilkinson et al., 2015). A study conducted by Jacobs et al., 2014 in our 




laboratory identified circulating BC strains in at least 4.6% of their study population, 
followed by another recent study in our laboratory conducted by Wilkinson et al., 2015 that 
also identified other non-C subtypes: B, A, G, URF_AD and URF_AC circulating in the 
Western Cape (Wilkinson et al., 2015). The genetic diversity of HIV in several regions of 
south Africa have been studied (Williamson et al., 1995; Hemelar et al., 2006; Bredell et al., 
1998; Pillay et al., 2002). Thus far, no reports have been documented in the remote regions of 
the Western Cape Province. The role that HIV-1 diversity plays in the South African 
pandemic need to be investigated, because some study reported that HIV-1 diversity poses a 
major challenge on a wide spectrum of fields such as vaccine development and diagnostics 
(Buonaguro et al., 2007; Peeters et al., 2003) and cART outcomes (Spira et al., 2003).  
1.2.5. HIV life cycle 
A summary of the HIV life cycle is illustrated in Figure 1.5. HIV mainly infects the white 
blood cells (leukocytes) of the human immune system. This is mainly CD4+ T-cells, 
Dendritic cells (DC), CD4+ monocytes, cytotoxic T-lymphocytes (CTLs) and macrophages 
(Stebbing et al., 2004). After the onset of infection the virus can be present in bodily fluids 
such as blood plasma, in peripheral blood mononuclear cells (PBMCs) as well as in primary 
and secondary organs of the immune system such as the lymph nodes and central nervous 
system (CNS) (Pierson et al., 2000; Stebbing et al., 2004). 
HIV infection starts when the virus attaches its own glycoprotein (gp120) to the host CD4+ 
cell receptor and the chemokine core-receptors, either CCR5 and / or CXC4 of leukocytes 
and then penetrate the human host cell (Regoes & Bonhoeffer, 2005). The CCR5 and CXCR4 
co-receptors are the main chemokine receptors that are used by HIV for entry in vivo 
(Clapham & McKnight, 2002). Following attachment, the viral lipid Envelope (Env) fuses 
with the cellular membrane and releases the HIV core, consisting of enzymes, proteins and 
genomic ribonucleic acid (RNA), into the host cytoplasm. Viral uncoating involves cellular 
factors and the viral proteins MA, Nef and Vif. (Hirsch & Curran, 1990; Harrich & Hooker, 
2002). Once the HIV viral core is released into the cytoplasm, the RT enzyme, reverse-
transcribes the viral RNA into a full-length double-stranded complementary deoxynucleic 
acid (cDNA). Once the proteins, enzymes and newly formed viral cDNA are transported to 
the nucleus of the host cell, the HIV IN  incorporates the viral DNA into the human host cell 
genome (Craigie and Bushman, 2012). When the viral DNA is successfully integrated into 
the human genomic DNA, the provirus RNA can be transcribed with the help of Tat, which 
binds to the 5’ end long terminal repeats (LTR) region of the incorporated viral DNA, as the 




host polymerase recognizes the integrated viral DNA as part of the host genomic DNA 
(Craigie and Bushman, 2012). The persistent of HIV within the reservoirs remains a major 
challenge for viral eradication. Thus, therapeutic interventions are urgently needed focusing 
on the strategies to eliminate the HIV reservoirs, because the persistence of latently infected 
cells in the reservoirs gives no hope of HIV cure, yet. (Siliciano et al., 2006). 
Once the viral RNA is transcribed the viral messenger RNA (mRNA) is initially spliced and 
exported out of the nucleus, with the help of Rev, to the cytosol for translation with the help 
of cellular machinery (Briggs et al., 2003). Assembly of the HIV-1 viral occurs within the 
plasma membrane of the infected host cell. The HIV-1 Gag polyprotein play a major role in 
mediating all the necessary steps required for virion assembly (Ono & Freed, 2001). Gag 
oligomer polyproteins interact with the genomic DNA in the plasma membrane and 
multimerize further to form spherical immature capsids and prepares for packaging into new 
progeny virus. The newly formed virus leaves the host cell by budding, followed by the last 
step of virus maturation occurs with the viral proteins cleavage of the Gag and Gag-Pol 
polyprotein precursors to form the mature Gag and Pol proteins. The generated virus is free 
to infect other cells of the host cell (Roshal et al., 2001). 





Figure 1.5: HIV life cycle. 
The HIV life cycle steps consist of viral attachment, entry, reverse transcription and integration of the viral 
DNA into the host DNA. This is followed by export of the viral proteins as well as viral assembly, budding, and 
maturation of viral particles. The target sites of the three classes of inhibitors, reverse transcription, integration 
and maturation, are indicated (Pomerantz & Horn, 2003; Turner & Summers, 1999). 
1.3. HIV-1 Enzymes of the pol gene 
The HIV-1 pol gene encodes three viral enzymes namely PR, RT, and IN. Most of the drugs 
thus far were designed targeting the pol gene because this region was identified as the 
efficient target site for antiretroviral drugs to inhibit HIV replication. Our study focused on 
HIV diversity of the pol region because this region is commonly regarded as the gene that 
confers HIV-1 drug resistance, interfering with the efficacy of cART and most of the drugs 
targeting these regions have successfully proved to control the virus to undetectable level. 
The functions of these enzymes in the HIV-1 viral life cycles are explained in section 1.3.1 - 
1.3.3 and the mechanisms of PI, RT and IN inhibitors are explained in section 1.4.3. 




1.3.1.The Protease (PR) Enzyme 
The HIV-1 Protease (PR) enzyme is a homodimer structure of two non-covalently identical 
monomers structures, which each is 99 amino acids long. A structural model of the HIV-1 PR 
homodimer is presented in Figure 1.6. The HIV-1 PR enzyme plays an important role in the 
life cycle of the retrovirus by post-translation processing of the precursor viral Gag and Gag-
Pol polyproteins to yield essential mature viral structures and functional proteins (Oroszlan et 
al., 1990). Each monomer consists of a conserved triad, Aspartyl proteases on the active 
region site region 25-27 and forms the part of the catalytic site. The MA, CA, NC and p6 
proteins are produced by the Gag polyprotein. The PR, RT and IN proteins are also produced 
from the Gag polyprotein when 9 different peptide sequences are recognised by the active 
site where it cleaves on the hydrophobic pockets (Erickson et al., 1999). Within each 
monomer, there is an extended β-sheet region (a glycine-rich loop) known as the flap that 
plays a role in the substrate-binding site by allowing the substrate to enter and bind to its 
binding site and closes down the active site upon substrate binding (James & Sielecki, 1985). 
Development of the drugs to fight against the HIV-1 life cycle have been designed to target 
the active site of the matured Protease enzyme (Vondrasek et al., 1997). The PR of subtype C 
is highly conserved and consists of different amino acidsequence in comparison with other 
subtypes A, B and D (de Oliveira et al., 2003; Gordon et al., 2003), which may potentially 
play a role in viral replication capacity and resistance acquisition (Kantor et al., 2006; 
Ceccherini-Silberstein et al., 2009). 
 
Figure 1.6: Structural model of HIV-1 PR. 




Homodimer labelled with the protease inhibitor resistance mutations. The polypeptide backbone of both 
protease subunits (positions 1–99) is shown in Figure 1.6. The active site (positions 25–27) is also displaced. 
The Protease was co-crystallized with a protease inhibitor, which is displayed in space-fill mode. 
 
1.3.2. The Reverse Transcriptase (RT) Enzyme 
The RT enzyme contains three distinctive enzymatic activities namely; RNA template-
dependent DNA polymerization, RNase H degradation of the RNA and DNA template-
dependent DNA polymerization, enabling the synthesis of the linear double-stranded DNA. 
The latter is inserted into the human genome by the IN from a single-stranded viral RNA 
genome (Goff, 1990). HIV-1 RT exists as an asymmetric heterodimer consisting of two 
related Polypeptide subunits p66 and p51 (DiMarzo-Veronese et al., 1986). The p66 and p51 
subunits are derived through cleavage by the viral PR, from a Gag-Pol polyprotein that is 
synthesized from a unspliced viral single-stranded RNA (di Marzo Veronese et al., 1986). 
The p51 subunit is composed of the first 450 amino acids of the RT gene. The p66 subunit 
consists of 560 amino acids in lengths and  is encoded by RT gene, while the p51 subunits 
consists of the first 450 amino acids of the RT gene. Although p66 and p51 share the same 
450 amino acids terminus, their relative organizations are significantly different. The longer 
subunit of the RT gene p66, contains the active site for carrying the enzymatic activities of 
the RT polymerase and RNase H and the DNA-binding “groove; the smaller p51 subunit 
carries no enzymatic activity and plays a role in the structural activity. The p66 is made of 
five subdomains namely: the “fingers”, “palm”, and “thumb” subdomains, playing a role in 
polymerization, and the “connection” and “RNase H” subdomains (Huang et al., 1998; 
Kohlstaedt et al., 1992). All of the five p66 subdomains mentioned form a nucleic-acid 
binding cleft, whereas the “connection” and the “thumb” of the small subunits form the floor 
of the binding cleft. The binding cleft is structured in a way that the nucleic acid touches both 
the polymerase and the RNase H active site. The “thumb” of the p66 subunit is made up of 
two helices: the alpha H (αH) and alpha L (αI) helices help to position the template strand to 
interact with the primer to the active site of the RT enzyme. The DNA “primer grip” is a 
structure that compromises of two hairpins (the p66 β12- β13) that help in positioning the 3-
hydroxyl end of the primer terminus to the polymerase active site for the polymerization of 
the incoming nucleotide triphosphate (Jacobo-Molina et al., 1993, Xiong et al., 1990).  
The HIV-1 RT is considered as the major molecular target of the several antiretroviral 
therapies against HIV-1 replication (Men´endez-Arias, 2002; Sarafianos et al., 2009; 
Men´endez-Arias, 2013). The RT sequence is relatively conserved region among HIV-1 




subtypes, but differences exist between subtypes B, C and between other viral subtypes. This 
includes differences on the effect of virus replication, frequency and the location of 
polymorphisms and on the development of different resistant pathways mechanisms in 
response to treatment with the RT inhibitors (Armstrong et al., 2009; Rhee et al., 2006; 
Kantor et al., 2005; Grossman et al., 2001; Novitsky et al., 2007). 
 
Figure 1.7: Structural model of HIV-1 (RT)  
The polypeptide backbone of the complete p66 subunit (positions 1–560), and DNA primer and template 
strands are shown. This model is based on the structure provided by Kohlstaedt & Steitz, 1992 in which the 
RT is co-crystallized with nevirapine, which is displayed in space-fill mode. The positions associated with 
NNRTI resistance are shown surrounding the hydrophobic pocket to which nevirapine and other NNRTIs 
bind. 
 
1.3.3. Integrase (IN) Enzyme 
The HIV-1 IN is essential for the chromosomal integration of the newly synthesized double-
stranded DNA into the host genomic DNA. The Intergrase enzyme is responsible for the 
insertion of the viral DNA into human genomic DNA using a two-step mechanism reaction. 
During the first mechanism, called 3’ processing, two GT nucleotides bases are removed 
from each 3’ end of the long terminal repeat of the viral double-stranded DNA synthesized by 
the RT enzyme. The second mechanism is called DNA strand transfer, whereby a pair of 
transesterification reactions integrate the 5’ ends of the viral DNA into the backbone of the 
host genomic DNA (Craigie & Bushman, 2012). HIV-1 IN (32-kDa) is composed of 288-
amino acid and is synthesised from the C-terminal portion of the pol gene by the HIV PR 
during maturation structure and function of HIV-1 IN (Chiu & Davies, 2004). HIV-1 IN is 




comprised of three domains: A, the catalytic core domain (amino acids 50 – 212); B, the N-
terminal domain (NTD) (amino acids 1 – 49) and the C-terminal domain (amino acides 213 – 
288), Figure.1.8 (Chiu & Davies, 2004). The NTD enhances IN multimerization through zinc 
coordination (HHCC motif) and promotes the concerted integration of the two viral cDNA 
ends into the host cell chromosome. The C-terminal domain is responsible for sequence-
independent, sequence-independent DNA binding to stabilize the IN–DNA complex 
(Marchand et al., 2006a). Each HIV-1 IN molecule consists of one catalytic site and has 
separate DNA binding sites for the ends of linear viral DNA and host cell DNA. The 
substrate of the enzyme is short double-stranded oligonucleotides corresponding to termini, 
called att sites. The activities of the integrase gene include the cleavage of deoxythymidylate-
deoxythymidylate (TT) dinucleotide from the 3’ of double-stranded att site substrate, the 
cleavage of double stranded target DNA to produce a staggered 5 base overhang and the 
transfer of activity in which the recessed 3’ end in the substrate DNA is joined to the 
5’phosphoryl end in the target DNA. 
 
Figure 1.8: Structures of the three domains of HIV-1 integrase shown as ribbon diagrams. 
A, the catalytic core domain; B, the N-terminal domain;C, the C-terminal domain. The drugs are designed to 
target the highly conserved Catalyic Core domain (A) (Robert, 2001). 
1.4. Combination antiretroviral (cART) 
Since the discovery of AIDS, tremendous efforts have been made in the development of 
antiretroviral compounds that target the different steps in the life cycle of HIV-1. cART has 




transformed HIV-1 infection from an acute illness to a controllable chronic disease, if 
managed correctly. Dramatic reductions of morbidity and mortality have been achieved since 
the wide-scale use of cART, however no cure has been found (Severe et al., 2005; Egger et 
al., 2008). A major problem that interferes with the success of cART is the emergence of 
drug-resistant variants in patients under treatment, which complicates treatment options and 
hampers good prognosis (Quiros-Roldan et al., 2001; Rousseau et al., 2001; Winters et al., 
2000; Lorenzi et al., 1999; D’Aquila et al., 2002; Yeni et al., 2002). 
1.4.1. Natural resistance mechanisms to HIV-1. 
In this section, I discuss the ability of how the human immune system is able to resist HIV-1 
naturally. There are individuals who are resistant to HIV/AIDS without the use of cART, thus 
natural resistance. These individuals are divided into two groups: Individuals who are 
continuously exposed to HIV-1, but still remain uninfected (Fowke et al., 1996; Kaul et al., 
2001; Kaul et al., 2004) and long–term non-progressers (LTNPs) (Easterbrook et al., 1999). 
Three variants of chemokine-related genes associated with natural resistance to HIV infection 
have been studied extensively. These include CCR5-Δ32, CCR2-64I, and SDF1-3’A. CCR5-
Δ32 is a naturally occurring mutation leading to the deletion of 32 (bp’s) in the CCR5 gene 
(Nkenfou et al., 2013). Individuals who are homozygotes for CCR5-Δ32 confers natural 
resistance to HIV strains that use the CCR5 co-receptor (Galvani et al., 2005). The CCR5-
Δ32 allele is found in approximately 5–15% European Caucasians, while it is not found in 
Africans and East Asians (de Silva, 2004). A mutation that exists on -2459 (A/G) in the 
CCR5 promoter has indicated a delay in progression to AIDS and seropositive individuals 
with the G/G genotype display slower progression to AIDS than those with the A/A genotype 
(Knudsen, 2001). 
A polymorphism of CCR2-V64I creates a change in which a Valine within the first 
transmembrane segment of the receptor was substituted by an Isoleucine (Smith, 1997). The 
allele frequency does not vary much among populations, with an average frequency of 10–
20%. CCR2-64I plays no role in the onset of HIV-1 infection, but heterozygotes for this 
allele were found to experience delayed progression to AIDS compared to those than 
homozygotes for the wild-type allele (Smith, 1997).  
Genetic mutations in human beta defensins (HBD) are shown to be protective against HIV-1 
infection. Homozygosity for the A692G polymorphism in DEFB1 was reported to be 
significantly more frequent in ESNs than in SPs (Zapata et al., 2008). Polymorphism of SDF-




1-3’ in the SDF-1 gene 21 showed a delayed progression rate to AIDS in homozygous 
individuals (Dezzutti et al., 2000; Winkler et al., 1998). A study conducted in individuals 
residing in Kenya showed that the extent of Human Leukocyte Antigen (HLA) discordance 
between mother and neonate plays a major role in natural resistance to vertical transmission 
of HIV-1 (MacDonald et al., 1998). Further studies also showed that saliva that contains a 
high level of SLPI were associated with low incidence of HIV-1 among neonates who 
acquired the disease during lactation after the first lactation month, meaning that SLPI can 
protect vertical transmission (Farquhar et al., 2002). Tripartite motif (TRIM) proteins 
(TRIM5α) are involved in protection against HIV-1 replication. TRIM5α found within the 
rhesus monkey (TRIM5αrh) blocks the HIV-1 by degrading the HIV before it undergoes 
reverse transcription (Reymond et al., 2001). Therefore, mutations within TRIM5 protect 
individuals against HIV-1 infection (Javanbakht et al., 2006). APOBEC3G was discovered to 
be associated with the inhibition of HIV-1 infection by reducing the fitness of Vif protein-
deleted strains of HIV, thereby blocking the integration of the viral cDNA into the human 
genome (Sheehy et al., 2002). Further support for this concept stems was from data by Jin et 
al., 2005, showing correlations between APOBEC3G levels, CD4+ T cell counts and viremia 
in a cohort of LTNP indicating a role of this protein in the control of HIV disease progression 
(Jin et al., 2005). 
1.4.2. Mechanisms of HIV-1 antiretroviral drugs  
In the early 1990s, ART regimens were provided as monotherapy. In most cases Nevirapine 
was given for the prevention of Mother to Child Transmission (pMTCT), while  Zidovudine 
(AZT) was given as monotherapy in patients with symptomatic HIV infection. However, 
monotherapy led to the quick development of RAMs. Thus, HIV-1 care changed the 
administration of monotherapy to use combinations of antiretroviral drugs known as highly 
active antiretroviral treatment (HAART), today referred as cART (Collier et al., 1996; 
D’Aquila et al., 1996). The development of cART has resulted in greater suppression of HIV 
from replicating, thus reducing mortality and morbidity (Hirsch et al., 2008) and prolonging 
the life span of HIV infected individuals (Fauci et al., 1996). 
There are currently five classes of cART drugs that are available that target the HIV-1 life 
cycles. This includes nucleoside and nucleotide reverse transcriptase inhibitors (NRTIs and 
NtRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), protease inhibitors (PIs), 
integrase inhibitors (InSTIs) (also termed integrase strand transfer inhibitors) and entry 
inhibitors (Panel on Antiretroviral Guidelines for Adults and Adolescents, 2015). Most of the 




designed cART work in a manner that attempt to exhibit activity that will inhibit viral 
replication by targeting RT, PR, IN or chemokine receptors used by the virus to enter the 
human host cell (Johnson et al., 2003). 
The nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) were the first ART 
regimens to be approved by the Federal Drug Administration (FDA) for the use in the 
treatment of HIV-1 infection (Young, 1988). NRTIs inhibit the HIV replication by becoming 
incorporated into the viral DNA and interrupt viral replication via competitive with cellular 
deoxynucleoside triphosphates and result in DNA chain termination (Weller, 2001). 
Moreover, NRTIs play an important role in the pMTCT and their role in treatment as 
prevention (TasP) and pre-exposure prophylaxis (PrEP) is being extensively investigated 
(Gupta et al., 2012). Since 2001, pregnant mothers and infants were recommended to use 
Nevirapine (NVP) as part of the pMTCT program (Pillay et al., 2008a), while in the Western 
Cape province of South Africa , a combination of AZT and NVP was administered for 
pMTCT between 2004 and 2010 (Draper et al., 2008). The second generation RT inhibitors, 
the NNRTIs are a set of drugs that act as non-competitive inhibitors of HIV-1 RT-DNA by 
binding and physically block the the polymerase activity of the RT enzyme of HIV-1 ( De 
Clercq, 1998). InSTIs are the new class of cART therapy that are designed specifically in 
blocking intergrase enzyme, a process whereby HIV proviral DNA is incorporated into the 
human host cell genome with the help of intergrase enzyme. Currently, there are only three 
INSTIs: [Raltegravir (RAL), Elvitegravir (EVG) and Dolutegravir (DTG)] that have been 
approved by the FDA (http://www.fda.gov). PIs are designed to target and actively bind the 
active site of the protease enzyme, thereby inhibiting the HIV-1 PR from cleaving the two 
Gag and Gag-Pol precursor proteins that are responsible for the production of new immature 
non-infectious virions (Karacostas et al., 1989). Fusion /entry inhibitor attempt to block the 
fusion of HIV with the host cell before it penetrates the host cell and start to replicate 
(Nagashima et al., 2001). 





Figure 1.9: The figure illustrates the main steps in the HIV-1 replication cycle and the inhibitory site 
The inhibitory antiretroviral drugs (green), and the step of the life cycle that they inhibit are indicated. Also 
shown are the key HIV restriction factors (tripartite motif-containing 5α (TRIM5α), APOBEC3G, SAMHD1 
and tetherin; red) and their corresponding viral antagonist (Vif, Vpx and Vpu; blue). CCR5, CC-chemokine 
receptor 5; LTR, long terminal repeat; NRTIs, nucleoside reverse transcriptase inhibitors; NNRTIs, non-
nucleoside reverse transcriptase inhibitors (Laskey et al., 2014). 
 
1.4.3. HIV-1 drug resistance testing. 
The emergence of HIV-1 drug resistance has been an important limiting factor that interferes 
with the success of cART. The accumulation of retrospective and prospective data has led 
three expert panels to recommend the routine use of HIV-1 drug resistance testing in the 
treatment of HIV-infected patients (EuroGuidelines Group for HIV Resistance, 2001; Hirsch 
et al., 2000; USA Department of Health and Human Services Panel on Clinical Practices for 
Treatment of HIV Infection, 2000).  
South African cART guidelines recommend the use of NNRTI and two NRTIs as the first-
line cART regimen and two NRTIs, a ritonavir (RTV)-boosted PI (bPI), usually Kaletra, as 
the second line therapy (NDOH, 2015). The South African cART drug resistance testing 
guidelines recommend that all persons (children and adults) who are experiencing failure on 
first-line therapy with a viral load of two measurements >1 000 RNA copies/ml as an 
indicator of therapy failure, to undergo resistance testing, combinedwithadherence 




councelling (Cozzi-Lepri, 2009; Cozzi-Lepri., 2012). HIV-1 drug resistance testing can be 
assessed as either genotypic or phenotypic (Hirsch et al., 2003; Haubrich et al., 2001). Both 
assays are recommended as an integral part of HIV clinical care, such as selection of active 
drugs when changing cART regimens of the patient or individuals experiencing virological 
failure, monitoring, and surveillance the prevalence of drug resistance within individuals who 
are on cART. HIV-1 drug resistance surveillance and monitoring depend predominantly on 
sequences analysis of the pol gene to detect drug RAMs known to limit the success of the 
particular regimens (Clavel and Hance, 2004). 
HIV-1 genotypic resistance testing assay involves sequencing of the PR and RT part of the 
pol gene to detect the presence or absence of the mutations that are known to confer 
resistance to cART (Eshleman et al., 2004). Genotypic resistance testing is commonly used in 
the diagnostic setting because of wider availability, affordability and it is less time 
consuming. After sequencing the patient HIV genome sequence is uploaded to a database 
with known algorithms of resistance detection associated with resistance mutations in the RT, 
PR, IN and envelope genes provides a useful guidance for interpreting genotypic resistance 
test results for HIV-1. The Stanford HIVDR database (http://hivdb.stanford.edu) is the most 
commonly used and up to date to interpret resistance results, but there are other available 
databases such as CPR (http://cpr.stanford.edu) and the SATuRN RegaDB Clinical 
Resistance Database to analyse and interpret resistance results.  
Phenotypic resistance testing is an in vitro assay that measures the capability of HIV-1 
isolates to replicate in the presence of different drugs at different concentrations. The 
concentration that block HIV-1 isolate growth by 50% [IC50] is calculated and results can be 
reported as fold-change in concentration of an inhibitor (IC50) (i.e. Fold resistance) for each 
HIV-1 (Lanier et al., 2004; Miller et al. 2004). 
1.4.4. HIV drug RAMs. 
HIV-1 drug RAMs in Africa are likely to increase in parallel with the wide scale-up of cART 
(Bennet et al., 2009). Several studies conducted in South Africa showed that many 
individuals who are on cART have high and / rapid frequency accumulation of NNRTI and 
other mutations, even while on first-line regimens (Marconi et al., 2008; Sunpath et al., 2008; 
Hoffmann et al., 2009; Barth et al., 2008). HIV transmitted drug resistance has also been 
documented in recent studies conducted in South Africa where a prevalence appears to be 
<5% (Barth et al., 2008; Jacobs et al., 2008; Pillay et al., 2008a; Pillay et al., 2008b). 




There have been reports documented based on the development and evolution of 
antiretroviral drug resistance between HIV-1 B subtypes and several non-B subtypes major 
(M) group. M group HIV-1 subtypes are known to possess naturally occurring 
polymorphisms that causes change on several codons of the PR and RT and because of the 
change in the sequences of codons might predispose viral isolates to encode amino acids that 
are implicated in development of antiretroviral drug resistance (Holguin et al., 2002; Kantor 
et al., 2002). HIV-1 diversity can potentially influence the different level of treatment 
efficacy among individual infected by non-B subtypes. This is supported by the fact that HIV 
subtypes naturally differs by as much as 35% of the genetic content (Brenner et al., 2007; 
Kantor et al., 2006). Thus, a high degree of HIV-1 genetic diversity poses a greater challenge 
of producing the ART that is capable of inhibiting the enzymes of the pol gene among 
various subtypes of infected patients (Kantor & Katzenstein, 2003). 






Thus, the aim of this study was to investigate the HIV-1 diversity in the remote areas of the 
Western Cape Province of South Africa (Cape Winelands, West Coast and Overberg). 
1.6. Objectives 
The objectives of this study were: 
 To obtain recent HIV-1 viral load (VL) samples for HIV-1 genotyping. 
 To identify HIV-1 subtypes through phylogenetic analysis in order to characterize 
HIV-1 diversity in the Western Cape Province of South Africa. 
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A total of 205 HIV-1 Viral Load (VL) samples were used for HIV-1 genotyping and 
screening for RAMs during this study. The Western Cape Province have well-established 
consolidated guidelines for HIV treatment that have specific objectives, one of which is to 
use viral load testing as a preferred approach method for monitoring the success of cART. 
Viral load testing is also used as a tool for diagnosis of treatment failure, with consecutive 
high viral loads, after three months on cART, meaning the patient is likely failing therapy. 
Briefly, the materials used in this study are listed in this chapter.  
 
2.2. Ethical permission 
Ethical permission for this study was obtained and approved by the Human Research Ethics 
Committee at the Faculty of Medicine and Health Sciences at Stellenbosch University 
(Tygerberg Campus), South Africa. For ethical clearance, ethics permission was granted in 
2015 and the project was registered under the application protocol number N15/08/071. It 
was renewed in 2016 (APPENDIX A). We obtained a waiver for the collection of diagnostic 
samples. All our work was conducted according to the ethical guidelines and principles of the 
international Declaration of Helsinki 2013, South African Guidelines for Good clinical 
Practice and the South African Medical Research Council (MRC) Ethical Guidelines for 
Research.  
2.3. Equipment, commercial assays, enzymes and chemicals 
The list of all the reagents, equipment, chemicals, software applications and assays used 
during the course of the study to characterize the Cape Winelands, Overberg and West Coast 
cohort samples are given in this chapter. In Table 2.1 the lists of chemicals, kits, and enzymes 
used are shown. In Table 2.2 the equipment needed to perform the necessary assays and 
analysis are presented, while the commercial packages used are given in Table 2.3. Buffers 
and additional media are listed in Table 2.4. Miscellaneous products used are listed in Table 
2.5. The suppliers and lot numbers are provided where applicable. The ® and ™ designations 




indicate that the products are either registered or trademark properties of the suppliers they 
are provided from.  
Table  2.1: List of chemicals and kits used in the study 
Chemical or commercial products 
and kits used 
Company Lot number 
1 Kb DNA Ladder Promega, USA 0461505 
5x Gelpilot® Loading Dye Qiagen, Germany 151051304 
Agarose Lonza Rocland, USA 0000381826 
BigDyeTM Terminator cycle 
sequence ready Kit 
Applied Biosystems, USA 1508055 
dNTP´s Promega, USA 002547 
GoTaq® DNA Polymerase Promega, USA 0000106979 
Nuclease free water Promega, USA 145045078 
QIAamp Viral RNA Mini Kit Qiagen, Germany 151017169 
QIAquick PCR Purification Kit Qiagen, Germany 151026478 
Sam Solution Applied Biosystems, USA 1410046 
SuperScsript ® III one -step RT with 
Platinum Taq kit DNA Polymerase 
Invitrogen, USA 1257-035 
BigDye X-Terminator® purification 
kit  
Applied Biosystems, USA 1509067 
 
 
Table 2.3: Equipment used to perform sample analysis 
Equipment   Supplier 
ABI prism® 310 Genetic Analyzer Applied Biosystems, USA 
UVItec Gel Documentation System UVItec Limited, UK 
Beckman Coulter Allegra ™ 6R centrifuge Beckman Inc, USA 
geneAMP® 9700 PCR system Applied Biosystems, USA 
Microfuge® 16 Beckman Inc, USA 
Labcon® FSIE shaking incubator Labcon Ltd, RSA  
Nanodrop™ ND 1000 Nanodrop Technologies Inc, USA 
Vortex Mixer VM 300 Gemmy Industrial Corp, Taiwan 





Table 2.4: Software programs and online tools used in sequence analysis 
Software package References and/or licensed companies 
Sequencher v 4.8 Gene Codes Corporation, Ann Arbor, USA 
ClustalW v 2.1 Thompson© et al., 1997 
MEGA 6.0 Tamura et al., 2011 
Geneious Biomatters Ltd, New Zealand 
BioEdit v5.0.9 Hall, 2003. Ibis Biosciences, USA 
 
Table 2.5: Databases used in the analysis of sequences 
Databases Web Address 
Los Alamos National Laboratory HIV Sequence Database http://www.hiv.lanl.gov 
Stanford HIV RT and Protease Sequence Database http://hivdb.stanford.edu 
BioAfrica http://www.bioafrica.net 
Calibrated Population Resistance (CPR) http://cpr.stanford.edu 
Sequence-Specific subtype analysis (REGA) http://hivdb.stanford.edu 





Table 2.6: Miscellaneous products used 
  
Material Supplying Company 
Glassware Labotec, RSA 
Laboratory liquids (Ethanol, Methanol) Sigma-Aldrich, USA 
Laboratory wear Labotec, RSA 
Parafilm Sigma-Aldrich, RSA 
Pipette tips Thermo Fisher Scientific, RSA 
Pipettes Thermo Fisher Scientific, RSA 
Plastic material Thermo Fisher Scientific, RSA 
Sterile filters and filter paper Thermo Fisher Scientific, RSA 
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This study was a retrospective study. The samples were previously used for HIV-1 viral load 
quantification to monitor the success of cART and to diagnose the treatment failure through 
analysis of the pol gene of the HIV-1 viral genome. In this study, we only selected samples 
from the Western Cape Province districts for further analyses. Briefly, after HIV-1 viral RNA 
extraction from the plasma samples, the viral nucleic acid was used as a template for the 
reverse transcription of the PR, RT and IN genomic regions of the pol gene. Viral RNA was 
converted into cDNA during reverse transcription. This was followed by PCR amplification. 
PCR products were visualized on an agarose gel, and then purified for DNA cycle 
sequencing. Positive PCR products were purified for analysis with the capillary 
electrophoresis from which DNA sequence data are acquired. The latter were further 
analyzed with online subtyping tools (REGA HIV Subtyping tool version 3; Recombinant 
Identification Program (RIP) 3.0; subtype classification using evolutionary algorithms 
(SCUEAL) software and through the Stanford University HIV Drug Resistance Database 
(HIVdb) 8.1. Multiple alignments formed of query sequences and reference sequences were 
created and used to infer phylogenetic trees (http://www.hiv.lanl.gov). Figure 3.1 shows a 
brief overview of the techniques used in this study. 
 
Figure 3.1: Flow diagram of molecular techniques used during the study. 
HIV-1 RNA extraction for viral loads was done using the automated Abbott m2000sp, while the RealTime 
Abbott m2000rt analyzer was used to determine the HIV-1 viral load (Abbott laboratories, Abbott Park, Illinois, 




USA). This was done by the National Health Laboratory Services (NHLS) diagnostic section of the Division of 
Medical Virology. The PR, RT and IN fragments of the HIV-1 viral genome were amplified by nested 
Polymerase Chain Reaction (PCR). The amplified gene fragments were visualized by agarose gel 
electrophoresis. The positive PCR products were purified and the nucleotide sequences of the HIV-1 genomes 
were directly determined. Detailed sequence verification and phylogenetic analysis were performed on all 
sequences obtained. 
3.1 Smple preparation for viral load  
HIV-1 patients were sent to and received at the diagnostic Virology Laboratory of the 
National Health Laboratory Services (NHLS), Tygerberg Hospital, Stellenbosch University 
in Cape Town, South Africa between January 2011 and December 2015. Samples were sent 
in Plasma Preparation Tubes). Approximately 2-3 ml plasma was stored from the 5 ml PPT 
blood samples by separating it from the red blood cells, white blood cells, and blood platelets. 
The plasma was collected after centrifugation (Beckman Coulter Allegra
™
 6R, Beckman Inc., 
USA) at 2000 revolutions per minute (rpm) for 10 minutes at 4°C. Sample selection was 
based on patient district location and patient viral load data of 2000 copies/ml. Gall et al., 
2012 showed that a sensitivity of at least 2000 copies/ml of the HIV-1 viral load is a limit of 
detection for the Superscript ® III one -step RT with Platinum Taq kit DNA Polymerase kit 
(Gall et al., 2012). In addition, this sensitivity of 2000 copies/ml was sufficient for PCR 
amplification of (99.3%) samples in their study. Only samples with sufficient plasma 
volumes left after HIV-1 viral load measurement were used for genotyping. Viral RNA was 
extracted from 1ml plasma using the high throughput M1000 robot extractor (Abbott 
Diagnostics, USA) in 200 uL volume of COBAS®AmpliPrep/COBAS® TaqMan® Wash 




3.2 HIV-1 viral load assay 
The Abbott RealTime 
®
 HIV-1 RNA Quantitative assay (Abbott Laboratories, Illinois, USA) 
was used according to the manufacturer’s instructions. Briefly, the assay is based on Reverse 
Transcription PCR (RT-PCR) technology with homogeneous real-time fluorescent detection 
and targets the pol IN gene to determine the viral load concentration. Labelled probes, 
specific for HIV-1, detect the DNA products in the sample after RT-PCR. The amplified 
product-probe hybrids were quantitated with a microparticle enzyme immunoassay (MEIA) 
on an automated Abbott Real Time
®
 Analyzer (Abbott Laboratories, Illinois, USA). A 
volume of 1000 μl was used to determine the number of HIV-1 RNA copies per ml in each 
plasma sample. The assay has a range of 50 to 1 million copies per ml if 1 ml sample volume 




is used. If a 200 μl sample is used, the detection limit ranges from 178 to 5 million copies per 
ml. The assay can detect and quantitate HIV-1 group M subtypes A-G, as well as HIV-1 
group O (Johanson et al., 2001; Zanchetta et al., 2000). The assay results were reported in 
copies/mL or international Units/mL (IU/mL). 
3.3. Viral nucleic acid extractions 
For the purposes of my study and for fresh RNA extraction, Viral RNA was extracted from 
140μl of plasma using the QIAamp viral mini kit (Qiagen GmbH, Germany) using the 
vacuum extraction system. The kit protocol was followed and RNA was eluted in 60μl of low 
salt elution buffer AVE containing 0.04% sodium azide. The Qiagen RNA extraction 
protocols are based on the silica-gel membrane principles developed by Vogelstein and 
Gillespie (1979). Briefly, lysing buffer is added to the patient sample to inactivate RNases 
and to ensure isolation of intact viral RNA. The sample is loaded onto the QIAamp Mini spin 
column, which  binds the RNA to a silica membrane. The buffering conditions are adjusted to 
provide efficient binding of the RNA to the QIAamp membrane of the
 
Spin Column during 
centrifugation or a vacuum step. Contaminants are efficiently washed away in two steps using 
two different wash buffers that ensure that residual contaminants are removed and improve 
the purity of the samples. High-quality RNA is eluted in a special RNase-free buffer, ready 
for direct use or safe storage. The purified RNA is free of protein, nucleases, and other 
contaminants and inhibitors. Isolated RNA was used for the molecular characterization of PR, 
RT, and IN, the region of the pol gene fragments. 
3.4. Polymerase chain reaction (PCR) 
The PCR method was used for the cycle sequencing reactions and HIV-1 genotyping 
reactions. The reactions were performed on the geneAMP
®
 9700 PCR system (Applied 
Biosystems, USA) with cycling parameters for the pol fragments described in the tables 
below. The ramp speed is calculated as the speed at which the PCR machine (thermocycler) 
switches between heating steps. A brief overview of the steps used to perform the PCR 
experiments are described as follows: A total volume of 5μl of RNA was used for pre-nested 
(first round) pol RT-PCR. The RNA was converted to generate cDNA by using the 
SuperScript® III one-step RT with Platinum Taq DNA polymerase (Invitrogen, USA) and 
then used as the template in a one-step PCR reaction. The SuperScript ® III one -step RT 
with Platinum Taq  DNA polymerase kit is a one-step method where primers targeting a 
specific gene of interest are being used for both the cDNA synthesis and PCR amplification, 




in a single reaction tube. The primer pairs used for pre-nested and nested pol amplification 
are given in Table 3.1, Table 3.3 and Table 3.5, whereas cycling conditions are presented in 
Table 3.2, Table 3.4 and Table 3.6. The primers were used at a final concentration of 
5µM/µL. The final concentrations of the remaining reagents were as follows: 2X Reaction 
Mix (a buffer containing 0.4 Mm of each dNTP, 3.2 mM MgSO4), SuperScript ® III 
RT/Platinum ® Taq Mix and nuclease free water was added to a make a final volume of 50μl. 
A second nested PCR was performed, using 5μl of the pre-nested PCR product as template. 
The final concentrations of reagents for nested PCR reaction were as follows 0.2mM dNTPs, 
1.5mM MgCl2, 5 x GoTaq Flexi buffer, 2.5 U/µlTaq DNA polymerase, water was added to a 
final volume of 50μl per reaction. All the PCR mixtures were prepared in 0.2 ml thin wall 
PCR
®
 tubes (QSP, Porex BioProducts Inc., USA). 
 
Table 3.1: Primers used in the amplification of the partial HIV-1 Protease gene 
products 
 










































Table 3.2: Cycling parameters of Protease gene products  
Cycling conditions for the Pre-Nested PR PCR assay 
Step Temperature Duration Cycles 
Reverse transcription 500C 30 min   
X 1 Initial denaturation 940C 2 min 
Denature 940C 15 sec   
X 40 
  
Anneal 600C 30 sec 
Extend 680C 1 min 
Final extension 680C 5 min X 1 
Cycling conditions for the Nested PR PCR assay 
Step Temperature Duration Cycles 
Initial denature step 940C 2 min X 1 
Denature 940C 20 sec   
X 40 Anneal 600C 30 sec 
Extend 680C 90 sec 
Final extension 680C 5 min X 1 
           Sec – seconds; min – minutes; °C – Degrees Celsius 
 
Table 3.3: Primers used in the amplification of the partial HIV-1 Reverse 
Transcriptase gene products. 













outer Mj3 R AGTAGGACCTACACCTGTC
A 
2480 -2499 941 





inner A35 F TTGGTTGCACTTTAAATTTT
CCCATTAGTCCTATT 
2530- 2564 798 
inner NE135 R CCTACTAACTTCTGTATGTC
ATTGACAGTCCAGCT 
3300-3334 




Table 3.4: Cycling parameters of Reverse Transcriptase gene products 
Cycling conditions for the Pre-Nested RT PCR assay 
Step Temperature Duration Cycles 
Reverse transcription 50
0
C 30 min  
X 1 Initial denaturation 94
0
C 2 min 
Denature 94
0








C 1 min 
Final extension 68
0
C 5min X  1 
Cycling conditions for the Nested PR PCR assay 
Step Temperature Duration Cycles 
Initial denature step 94
0
C 2 min X 1 
Denature 94
0
C 20 sec  
X 40 Anneal 60
0
C 30 sec 
Extend 68
0
C 90 sec 
Final extension 68
0
C 5 min X 1 
Sec – seconds; min – minutes; °C – Degrees Celsius 
 
Table 3.5: Primers used in the amplification of the partial HIV-1 Integrase gene 
products. 



























Table 3.6: Cycling parameters of Integrase gene products.  
Cycling conditions for the Pre-Nested PR PCR assay 
Step Temperature Duration Cycles 
Reverse Transcription 500 c 30 min   
X1 Initial denaturation 940c 2 min 
Denature 940c 15sec   
X40 
  
Anneal 550c 30sec 
Extend 680c 90 sec 
Final Extension 680c 10 min X1 
Cycling conditions for the Nested PR PCR assay 
Step Temperature Duration Cycles 
Initial Denature Step 950c 2 min X1 
Denature 950c 20 sec   
X40 Anneal 550c 30 sec 
Extend 700c 90 sec 
Final Extension 720c 10 min X1 
             Sec – seconds; min – minutes; °C – Degrees Celsius 
3.5. Agarose gel electrophoresis 
Gel electrophoresis is the standard laboratory procedure of separating and analyzing nucleic 
acids based on the molecular weight size. During agarose gel electrophoresis DNA molecules 
are separated by applying a constant electrical field to the electrophoretic apparatus. 
Negatively charged DNA migrates from anode to cathode through an agarose gel matrix, 
shorter molecules migrate faster and easily than longer molecules through the pore of the 
agarose gel matrix (Sambrook et al., 1989). 
All PCR products were visualized by agarose gel electrophoresis on a 1.0% agarose (Seakem 
LE® agarose; FMC BioProducts, USA) gel in 1 x TAE buffer (0.04 M Tris-acetate, 0.001 M 
EDTA). After the gel solution cool to about 60
0
C, GRGreen (Qiagen, Germany) was added to 
the solution to 1x final concentration to stain the gel. Samples were mixed with 6 x DNA 
loading dye (0.125% Bromophenol blue, 40% Sucrose) and approximately 5μl were loaded 
per lane on the agarose gel. Electrophoresis reactions were run at 75 V for a 50 ml agarose 
gel. A 1 kb DNA molecular weight marker (Promega, USA) was used as an estimation of 
DNA band size also included was a negative and a positive control. The DNA bands were 
visualized under an ultraviolet light at a wavelength between 280 and 320 nm and 
photographed with the Syngene™ GeneGenius computer system (Synoptics Ltd, United 




Kingdom). The expected fragment sizes for PR, RT and IN gene fragments were 507 bp, 798 
bp, and 985 bp, respectively. 
3.6. Purification of nucleic acids 
To remove the excess dNTPs, primers, enzymes and buffers that might interfere with the 
sequencing reactions the above mentioned-PCR products were purified with the QiaQuick 
PCR purification kit, according to the manufacturer’s instructions (Qiagen, Germany). The 
purification protocols are based on silica membrane spin protocols that allow for binding of 
nucleic acids to a silica membrane inside a spin column (Vogelstein & Gillespie, 1979; 
Sambrook et al., 1989). Briefly, 5 volumes of phosphate buffer (PB) was added to 1 volume 
of the PCR sample (example, 47 µl was added to 235 µl of buffer PB). DNA was bound to 
the spin column membrane by centrifugation using microfuge® 16 at a maximum speed of 13 
000 rpm (Beckman Inc) and washed once to remove any impurities that may still be present. 
DNA was eluted with 50μl of buffer EB (10 mM Tris-Cl, pH 8.5). The purified aliquot was 
stored at -20°C until the sequencing reactions were performed.  
3.7. DNA concentration determination 
The NanoDropTM system (NanoDrop technologies, USA) was used to determine the DNA 
concentration spectrophotometrically, using a 1µl input sample. DNA measurements were 
read at a wavelength of 260 nanometers (nm), while purity was determined by dividing the 
absorbance at 260 nm with the absorbance at 280 nm (Sambrook et al., 1989). Pure DNA has 
a value between 1.7 and 2.3. Lower values are indicative of protein contamination, while 
higher values indicate the presence of RNA in the sample. 
3.8. DNA cycle sequencing reactions 
DNA cycle sequencing reaction is performed in order to linearize the DNA fragment of 
interest and amplification of the labeled DNA. Briefly, each reaction was performed as 
follows: Approximately 50ng of the purified PCR products was used in the sequencing 
reactions. The BigDye
TM
 Terminator Cycle Sequencing Ready Reaction Kit (Applied 
Biosystems, USA) was used for the PCR-based sequencing reactions according to the 
manufacturer’s instructions. Briefly, 1μl of the Big Dye terminator enzyme mix (BigDye® 
Terminator Cycle Sequencing Kits, Applied BioSystems, USA), 5 pmol of primer, ~ 50ng of 
sample DNA, 2μl of 5x Sequencing Buffer (Applied BioSystems, USA) and Nuclease-Free 
water (Promega, USA) was added to each reaction to make up a final volume of 10μl. Each 




sequencing reaction was performed under the following conditions on a GeneAmp PCR 
System 9700 thermal cycler (Applied BioSystems, USA): Denaturation at 96
o
C for 10 
seconds, primer annealing for 5 seconds, annealing temperature according to sequencing 
primers, Table 3.7 and Table 3.8, and an elongation step at 60
o
C for 4 minutes. The cycles 
were repeated 25 times after which the samples were cooled down to 4
o
C. The latter reaction 
mixture was purified using the BigDye X-Terminator Purification Kit and analyzed on an 
ABI 3130XL genetic analyzer (Applied Biosystems, USA). 
The trace data files of each sequencing run were subsequently retrieved and imported into 
Sequencer v 4.8 (Gene Codes Corporation, Ann Arbor, USA). The quality of each 
chromatogram fragment was assessed manually. Each patient’s chromatogram fragments 
were assembled into a single contigue and manually proofread in order to assure good 
sequence quality. After the fragments were proofread, they were exported in a text file (.txt) 


















Table 3.7: Summary of primers and cycling conditions used for the sequencing of pol 
PCR fragments 
POL B was designed by Dr Jacobs, POL3D was designed by André Gareth Loxton, within the 
Division of Medical Virology 





*Annealing temperatures for sequencing primer sets were indicated in Tables above. 
3.9. Sequence quality control 
The online Quality control programme was used to examine the sequence sets for common 
problems: http://www.hiv.lanl.gov/content/sequence/QC/index.html. Results from the tool 
Primers F/R Annealing 
Temperature 
Oligonucleotide sequence References 
JA217 R 60°C CTTTTATTTTTTCTTCTGTCAATG Plantier et al., 2005 
30 PROT 2 R 60°C AATGCTTTTTCTTCTGTCAATGGC Plantier et al., 2005 
*POL b F 60°C CACTCTTTGGCARCGACC Jacobs personal 
communication 
Pol 1D F 60°C TCCCTCAAATCACTCTTTGGC Loxton et al., 2005 
AK 10 R 60°C TYCCCACTAAYTTCTGTATRT Plantier et al., 2005 
AK 11 F 60°C GTACCAGTAAAATTAAARCCAG Plantier et al., 2005 
*pol 3D F 60°C AATGTTGCACTTTAAATTTATCC Loxton et al., 2005 
NE 135 R 60°C CCTACTAACTTCTGTATGTCATTG
T 
Plantier et al., 2005 




Poli6 R 55°C ATACATATGRTGTTTTACTAARCT Engelbrecht personal 
communication 
Poli7 F 55°C AACAAGTAGATAAATTAGTCAGT Engelbrecht personal 
communication 
Poli8 R 55°C TAGTGGGATGTGTACTTCTGAAC Engelbrecht personal 
communication 
50 PROT 2 F 60°C TCAGAGCAGACCAGCAGCCCCA Plantier et al., 2005 
PCR steps Temperature Time Cycles 
Denaturation 96 ºC 10 sec  
25 X Annealing ºC* 5 sec 
Extension 60 ºC 4 min 




include: subtype (from RIP) 3.0, similarity (from HIV BLAST), phylogenetic (from 
Neighbour TreeMaker), stop codons and frameshifts (from GeneCutter) and hypermutation 
(from HyperMut). 
3.10. HIV-1 characterization using online subtyping tools 
All Sequence-Specific subtype analysis was executed with the REGA HIV Subtyping tool 
version 3; Recombinant Identification Program (RIP) 3.0; subtype classification using 
evolutionary algorithms (SCUEAL) software and through the Stanford University HIV Drug 
Resistance Database (HIVdb) 8.1. 
3.11. Sequence alignments and phylogenetic analysis 
In order to study the evolutionary relationships between the different strains of HIV 
sequences obtained during the study, phylogenetic analyses were used. Phylogenetic analysis 
is the means of inferring or estimating the pedigree of the inherited relationships among 
organism o molecules looking at the molecular level of the organism such as DNA and / or 
protein sequences. Sequence contigs obtained were aligned using the ClustalW version 2.0 
software package (Thompson et al., 2007) and manually edited using the BioEdit software 
package. Phylogenetic trees were infered with the Mega version 6.0 software package 
(Tamura et al., 2011). Reference sequences used in the phylogenetic analyses were retrieved 
from the LANL (http://www.hiv.lanl.gov/). 
3.12. Drug resistance analysis 
As we used pol sequences to study HIV-1 diversity, we were able to use the sequences to 
investigate the RAMs in our study cohort. For screening of the HIV-1 RAMs, the PR, RT, 
and IN fragments, FASTA formatted sequence files were deposited into the Stanford 
University HIV Drug Resistance database (HIVdb) online tools for analysis using the 
genotypic resistance interpretation algorithm version 8.1 (http://hivdb.stanford.edu/). Drug 
resistance mutations results were classified as either major or minor mutations. 
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4.1. Patient demographics 
Epidemiological and clinical data describing the population used in the study are presented in 
Table 4.1 and Figure 4.1. The study involved two hundred and five (205) HIV-1 Viral Load 
(VL) samples, 83 (40.49%) were male and 122 (59.51%) were female. The mean age of the 
patients was 34.41 years (range between 3 years 7 months to 63 years). The median viral load 
was 236317.2copies/mL (range between: 6166147 and
 
2035 copies/mL). Among the Western 
Cape Province HIV-1 samples analyzed in this study 129 (62.92%) live in Cape Winelands 
district, 29 (14.14%) in the Overberg district and 47 (22.92%) in the West Coast district. 
With our study samples, only 62/205 (30.2%) of patients indicated that they were receiving 
first-line cART at the time of sample collection. We are unable to indicate on which regimen 
the other patients were at the time of sample collection if any. The cART regimens are shown 
in APPENDIX B. 
Table 4.1: Summary of epidemiological and clinical characteristics of the Western Cape 
Province HIV-1 viral cohort from the different geographic regions. 
Parameters Cape Winelands (n=129) Overberg (n=29) West Coast (n=48) 
Age    
Oldest 63 years 59 years 52 years 
Average 33.8 years 34.2 years 35.8years 
Youngest 6 years 13 years 3 years 7 months 
Gender    
Male 48 14 21 
Female 81 15 26 
Viral Load    
Highest 3249561 3272216 6166147 
Average 201349.7 499256.6 212303.1 








Figure 4.1: Map of the Western Cape region of South Africa, with the origin of the patients, indicated. 
A total of 205 samples were analyzed during the study from the 3 districts: Cape Winelands (Bella Vista, n = 8; 
BrewelSkloof, n=2; Ceres, n=36 ;De Doorns , n=31; Mbekweni, n=16; N’duli Park, n=1; Paarl, n=3 ; Wolsely, 
n=2; Worcester, n=32; Zolani, n=1 ). Overberg (Bredasdorp, n = 4; Grabouw, n =23; Matjieskloof, n=1 ; 
Swellendam, n=1; Zwelihle, n=1.) and West Coast (ClanWilliam, n=5; Hanna Cotzee, n = 1; Malmesbury, 
n=27; Swartland, n=1; Vredenburg, n=3; Vredendal, n=6). 
 
4.2. HIV Viral load assays 
The gender, age, date of sample collection and VLs determined for each patient is given in 
APPENDIX C. The HIV RNA copies ranges between (6166147- 2035 cells per/ml). 
4.3. Viral nucleic acid extractions 
RNA was extracted from 205 HIV-1 viral cohort patient samples. A good quality RNA 
concentration level was obtained for all patient samples and ranged between 41.03 ng/μl and 
160.89 ng/μl. The purity levels of all samples were good, being above 1.70 (260/280). 
APPENDIX D. 




4.4. PCR and gel electrophoresis for the PR, RT and IN gene 
fragment 
For the PR and RT gene fragments PCRs were performed on all 205 viral RNA extracted 
samples. For the IN region, only 176 samples had sufficient RNA and plasma left after the 
genotyping of the PR and RT region. All the amplified gene fragments were visualized by 
agarose gel electrophoresis and further analyzed. 
4.4.1. PCR and gel electrophoresis for the PR and RT gene fragment 
From a collection of 205 patient samples, PCRs were performed on the pol (PR and RT) gene 
fragments of the HIV-1 genome. One hundred and seventy (82.9%) and 166 (80.9%) of the 
pol PR and RT fragment region showed positive bands after agarose gel electrophoresis, 
respectively (Figure 4.2 and 4.3). The partial pol fragments (PR and RT) were visualized by 
agarose gel electrophoresis along with a positive control and Non-template control (NTC). 
From 170 PR and 166 RT fragment that positively amplified, only 82 (40%) of the samples 
were successfully amplified in both the RT and PR gene regions and 74 (36.1%) samples 
could not be amplified with any of the primers for both the PR/RT, following extensive 
methods to optimize the PCR conditions (e.g. changing the concentrations of MgCl2 and/or 
slightly adjusting the annealing temperatures of primers as well as re-designing the primers). 
A summary of the PCR results is listed in Table 4.2. 
 
Table 4.2: Summary of the PCR results for the different fragments 
 PR RT 
n = Sample 205 205 
Positive 170 (82.9%) 166 (80.9%) 
 





Figure 4.2: Partial pol PR gene fragments amplified in nested PCR assay.  
After two rounds of amplification, the PR 507 bp was visualized on a 1% agarose gel. All samples were 
visualized on the agarose gel along with a 1kb molecular marker (M), Lane M: 1kb DNA Ladder, lane: 1-7 
patient samples. Lane PC: Positive control, Lane NC: Negative control. 
 
Figure 4.3: Partial pol RT gene fragments amplified in nested PCR assay 
After two rounds of Amplification, the RT 798bp was visualized on a 1% agarose gel along with a 1kb 
molecular marker (M), Lane M: 1kb DNA Ladder, 137-203 patient samples. Lane PC: Positive control, Lane 
NC: Negative control. 
 




4.4.2. PCR and gel electrophoresis for the IN gene fragment. 
PCRs were performed on the pol IN gene fragment of the HIV-1 genome. One hundred and 
forty-three (81.3%) IN fragments showed positive bands after agarose gel electrophoresis 
(Figure 4.4). A positive control and Non-template control (NTC) is included on the gel. 
Thirty-three (18.8%) samples could not be amplified with any of the primers for the IN. 
 
Figure 4.4: Partial pol IN gene fragments amplified in nested PCR assay.  
After two rounds of amplification, the IN 945 bp was visualized on a 1% agarose gel along with a 1kb molecular 
marker (M), Lane M: 1kb DNA Ladder, lane: 1-16 patient samples. Lane NC: Negative control and Lane PC: 
Positive control. 
4.5. Sequencing data quality. 
All positive amplified PCR products were purified and sequenced for the PR, RT, and IN 
fragments. Of the 170 (82.9%) PR region PCRs 116 (68.2%) samples were successfully 
sequenced in both overlapping strands and 33 (19.4%), samples were positively sequenced in 
one strand only, followed by 21 (12.6%) samples that were not successfully sequenced with 
any of the primers. For the RT region, of 166 (81.0%) positively amplified fragments, 103 
(62.0%) samples were positively sequenced in both strands, 38 (22.8%) samples were 
sequenced successfully in one strand only and 25 (15.1%) samples couldn’t be sequenced for 
any of the primers used. Of the 143 (81.3%) IN region PCR products, 108 (75.5%) samples 




were positively sequenced in both overlapping strands and 21 (14.7%) samples were 
positively sequenced in one strand only, followed by 14 (9.8%) samples that did not 
successfully sequenced with any of the primers used. All the sequences that were sequenced 
were checked for quality score and further edited manually with the Sequencer software to 
remove ambiguity nucleotides and sequences with quality less than 75.0% and fragments less 
than 200 bp. Further analysis was performed on the 62 (53.4%) PR, 103 (88.8%) RT and 93 
(86.1%) IN sequences with quality ≥75%. The majority of the sequences that were sequenced 
on the PR fragment, generated shorter fragments sequences which is less than (200bp) and 
the possible reason for generating shorter fragment might be that the primers were not 
specific to the binding site of the protease gene. And this was followed by re-designing of the 
primer (PolB_fwd: 5’-CACTCTTTGGCARCGACC-3’) that can sequence the partial PR 
fragment size of 507 bp. 
4.6. Sequence quality control 
All positive sequences were analyzed using the online Quality control tool to examine the 
sequence sets for common problems such as stop codons and frame shifts (from GeneCutter) 
and hypermutation (from HyperMut). When the online LANL QC tool indicated stop codons 
or frameshift, the sequences were re-read and verified. No Hyper- mutations was detected in 
all sequences after being re-read manually (http://www.hiv.lanl.gov).  
4.7. HIV-1 characterization using online subtyping tools 
Sequence-specific subtype analysis was executed with the REGA HIV Subtyping tool version 
3; Recombinant Identification Program (RIP) 3.0; subtype classification using evolutionary 
algorithms (SCUEAL) software and also through the Stanford University HIV Drug 
Resistance Database (HIVdb) 8.1. The following tables below are the results summaries of 
the subtyping tools used to analyses the fragment of the PR, RT, and IN region of the pol 
gene, as described in sections 4.7. Figure 4.5, is an example of one of the sequence 
(12_ZA_WC_CW_20_RT) grouped as subtype A1, using the online subtyping tools and 








Table 4.3: PR fragment region analysis of non-subtype C sequences using various online 
tools 
SEQUENCE CODE REGA RIP SCUEAL HIVDRD 
15_ZA_WC_CW_22_PR Unclassified C C C 
12_ZA_WC_OV_19_PR Unclassified C C C 
13_ZA_WC_CW_66_PR Unclassified C C C 
 
Table 4.4: RT fragment region analysis of non-subtype C sequences using various online 
tools 
SEQUENCE CODE REGA RIP SCUEAL HIVDRD 
14_ZA_WC_CW_49_RT B B B B 
13_ZA_WC_CW_31_RT A1 A1 A1 A1 
12_ZA_WC_OV_5_RT B B B B 
13_ZA_WC_CW_50_RT B B B B 
11_ZA_WC_CW_7_RT B B B B 
12_ZA_WC_CW_20_RT A1 A1 A1 A1 
13_ZA_WC_CW_52_RT C C A1,C C 
14_ZA_WC_WC_11_RT Unclassified C C C 
12_ZA_WC_CW_42_RT Unclassified C C C 
14_ZA_WC_CW_43_RT Unclassified B C C 
14_ZA_WC_CW_45_RT Unclassified C C C 
 
Table 4.5: IN fragment region analysis of non-subtype C sequences using various online 
tools. 
SEQUENCE CODE REGA RIP SCUEAL HIVDRD 
13_ZA_WC_OV_13_IN A1 A1 A1 A1 
12_ZA_WC_WC_8_IN B B B B 
12_ZA_WC_OV_15_IN B B B B 
12_ZA_WC_OV_16_IN B B B B 
13_ZA_WC_CW_54_IN B B B B 
14_ZA_WC_WC_16_IN B B B B 
13_ZA_WC_CW_20_IN Unclassified C C C 
12_ZA_WC_CW_37_IN Unclassified B B B 
14_ZA_WC_CW_12_IN Unclassified C C C 
12_ZA_WC_CW_40_IN A1 C A1 A1 
13_ZA_WC_OV_21_IN Unclassified C C C 
 










Figure 4.5: Analysis of sample 12_ZA_WC_CW_20_RT using three online HIV-1 subtyping tools. 
Example of one of the sample (12_ZA_WC_CW_20_RT) from Cape Winelands district that was classified as 
subtype A1, using three different online tools; A: REGA, B: RIP, and C: HIVDRD. All the three HIV-1 online 
subtyping tools classified the sequence as subtype A1. 
4.7.1. Recombinant Identification Program (RIP). 
All PR, RT, and IN Sequences were analyzed for subtyping using RIP; last accessed 
18/06/2016. The analysis of all 3 pol fragments region identified 14 Non-C subtypes. A 
summary of the results are shown in Table 4.3 to Table 4.5. 
4.7.2. Rega 3.0 subtyping analysis. 
All sequences were analyzed with the Rega 3.0 subtyping tool used to analyses the PR, RT, 
and IN gene fragment and classify all the sequences according to the HIV-1 subtypes, last 
accessed 03/07/2016 . Of 59/62 (95.2%) PR, 93/103 (90.2%) RT and 82/93 (88.2%) IN were 
identified as Subtype C respectively. However, three (4.8%) PR, four (3.9%) RT and four 
(4.3%) IN sequences designated with Unclassified report respectively, followed by one 
samples for PR identified as subtype A1. For the RT sequences four sample classified as 
subtype B, two sequences as subtype A1 and for the IN one as subtype A1, with five as 
subtype B. 
4.7.3. SCUEAL analysis  
SCUEAL identified three patient sequences for the RT gene as subtype A1 and four RT 
sequences as subtype B. For the IN two sequences were identified as subtype A1 and six 
sequences were characterized as subtype B. The remaining sequences for PR and RT were 




identified as subtype C together with all the remaining sequences sample for IN were 
identified as subtype C, last accessed on the 13/06/2016. 
4.7.4. Stanford University HIV Drug Resistance Database. 
Stanford University HIV Drug Resistance Database, last accessed on the 18/07/2016, only 
identified two sequences for the RT as subtype A1 and two sequences for the IN as subtype 
A1. However, the database also identified four B subtype for the RT and six B subtypes for 
the IN. All the remaining sequences for RT, PR and IN classified as subtype C.  
4.8. Sequence alignments and phylogenetic analysis 
4.8.1. Sequence alignment 
In order to study the evolutionary relationships of HIV sequences obtained during the course 
of the study, we aligned the study sequences with the group M reference sequences from the 
Los Alamos National Laboratory (LANL) HIV Sequence Database. Multiple alignments 
were generated to construct neighbour-joining trees. Phylogenetic analyses were used to 
validate and confirm the results obtained from different online subtyping tools. 
4.8.2. Construction of partial pol neighbour-joining tree. 
4.8.2.1. Construction of partial PR neighbour-joining tree 
A neighbour-joining tree (Figure 4.6) of PR was constructed using sequences obtained from 
the LANL database (http://www.hiv.lanl.gov). The analysis included 62 nucleotides 
sequences from this study. The majority of the sequences (n = 61; 98.4%) clustered with 
subtype C reference sequences, except one sequence (15_ ZA _WC_ CW_ 36_ PR) that 
clustered with the subtype H reference sequence. This does not correspond with the online 
subtyping tools that identified this sequence as subtype C. Due to the short DNA sequence 
generated for PR in many of the cases (less than 200 bp), the majority of sequences (n =54; 
48.3%) were excluded to construct a phylogenetic tree. The alignment was based on HXB2 
position 2145 to 2635. 
4.8.2.2. Construction of partial RT neighbour-joining tree 
In Figure 4.7, the RT phylogenetic tree is shown, 101 (98.1%) of sequences grouped with 
subtype C reference sequences. While 1/103 (0.95%) sequence (12_ ZA_ WC_ CW _42 
_RT) clustered with the subtype B reference sequences. In addition, another sequence (12_ 
ZA_ WC_ CW_ 20_ RT) clustered with subtype A1 reference sequences and corresponded 




with the Rega 3.0, RIP, SQUEAL and Stanford HIVDRD analysis. The alignment was based 
on HXB2 position 2668 to 3434.  
4.8.2.3. Construction of partial IN Neighbour-joining tree 
The IN phylogenetic tree is depicted in Figure 4.8. The tree identified four cluster groups. 
The majority of sequences 101(92.4%) clustered with subtype C reference sequences. 
However, three sequences (2.7%) clustered with subtype B (11_ZA_WC_CW_16_IN), 
(13_ZA_WC_CW_15_IN), (15_ZA_WC_CW_26_IN) and another three sequences 
(12_ZA_WC_CW_22_IN), (12_ZA_WC_CW_30_IN) (14_ZA_WC_WC_1 IN) clustered 
with subtype A1 reference sequences. In addition, one sample (12_ZA_WC_CW_5_IN) 
grouped as subtype D. The alignment was based on HXB2 position 4351 to 5069. 





Figure 4.6: Neighbour Joining tree of PR reference and query sequences.  
The phylogenetic tree was constructed in Mega 6v.1, with Kimura 2 parameter and consisted of cohort and 
query sequences approximately 205 bp in length. Bootstrapping was performed with 1000 replicates with 
significant values indicated on tree. Reference sequences are indicated in red colour and the study sequences are 
indicated in black colour. Majoriy of the sequence are classified as subtype C, with one sequence classified as 
subtype H. 





Figure 4.7: Neighbour Joining tree of RT reference and query sequences.  
The phylogenetic tree was constructed in Mega 6v.1 ,with Kimura 2 parameter and consisted of cohort and 
query sequences approximately 520 bp in length. Bootstrapping was performed with 1000 replicates with 
significant values indicated on tree. Reference sequences are indicated in red colour and study sequences in 
black colour. Majority of sequence are classified as subtype C, with two sequences identified as non-C subtype. 





Figure 4.8: A Neighbour Joining tree of IN reference and query sequences. 
Each query sequence are indicated in black colour. Bootstrapping was performed with 1000 replicates with 
significant values indicated on tree. Bootstrap value of greater than 70% is indicated on the condensed tree. 
Reference sequences are indicated in red colour and study sequences in black colour. Majority of sequence are 
classified as subtype C, with four sequences identified as non-C subtype. 




4.9. Analyses of RAMs 
As we used the pol sequences to study HIV-1 diversity, we could subsequently use the same 
sequences to look for RAMs amongst our sequences generated. The analyses of HIV-1 
RAMs were based on the pol gene targeting the PR, RT, and IN gene fragment that are 
commonly known to be the regions that are conserved with mutations that act against the 
effectiveness of HIV-1 cART. The PR, RT, and IN sequences were used for the analysis of 
HIV-1 RAMs in the three antiretroviral classifications namely: PIs, RTIs (NRTIs and 
NNRTIs) and INSTs using the Stanford HIV-1 drug resistance database. The Stanford HIV-1 
drug resistance database did not detect any major RAMs against PI and IN inhibitors. Minor 
RAMs detected was N88D, detected in 4 PR (3.7%) that cause low-level resistance especially 
against Nelfinavir, Figure 4.9 and Table 4.7. From the 93 IN sequences screened 15 (16.1%) 
had minor RAMs namely E157Q, G163EK, H51H, V151IV, L74I, L74IM, F121L, T97A, 
V151I, and V151IV, with only 9 (9.6%) of RAMs detected cause potential-low-level 
resistance against DTG, EVG and RAL and 6 (6.4%) of RAMs detected were found to cause 
low-level resistance against EVG and RAL, Figure 4.11 and Table 4.7. Of the 103 pol, RT 
sequences screened for RAMs 39 patients (37.8%) were confirmed on first line therapy and 
the remaining regimens were not indicated by the medical practitioner on the patient HIV-1 
viral load request form. HIV-1 viral load cohort treatment is given in APPENDIX B. In 63 
(61.7%) of the screened viral load patient sequences, major RTI RAMs were detected (Figure 
4.10). 34 (48.7%), of which first line therapy regimens were indicated on the patient HIV-1 
viral load request form the Stanford HIV-1 database  detected no RAMs against those 
sequences. Mutations related with resistance to NRTI were observed in 39 (36.1%) patients, 
M184V 31 (39.7 %), and K65R 24 (30.7%) being the most common ones. Seventy-one 
(63.5%) with non-NRTIs (NNRTIs) RAMs with K103N 47 (36.1 %) and V106M 20 (15.4 























E138A 7 5.3 D67N 3 3.8 
E138K 3 2.3 K219E 2 2.6 
F227L 4 3.1 K219EK 1 1.3 
G190A 8 6.2 K219Q 2 2.6 
G190Q 1 0.8 K65R 24 30.7 
G190S 1 0.8 K70R 2 2.6 
K101E 4 3.3 L74I 4 5.1 
K103N  47 36.1 M184I 1 1.3 
K103S 1 0.8 M184IM 1 1.3 
L100I 3 2.3 M184V 31 39.7 
V106M 20 15.4 T215F 2 2.6 
V106MV 4 3.3 
V179D 2 1.5 
Y181C 5 3.8 
Y181V 2 0.8 
Y188CY 1 0.8 
Y188H 11 8.5 
Y188L 3 2.3 
 











E157Q 1 3.3 D30N 100  
G163 1 3.3 
H51HL 1 3.3 
V151IV 1 3.3 
L74I 11 36.6 
L74IM 1 3.3 
F121L 1 3.3 
L74LM 1 3.3 
T97A 2 6.6 
V151I 8 26.6 
V151IV 2 6.6 
 
 





Figure 9: Observed drug resistance mutations against PR inhibitors. 
Stanford University HIV Drug Resistance Database detected only minor RAMs (N88D) in 4 

































Figure 10: Observed drug resistance mutations against RT inhibitors. 
Stanford University HIV Drug Resistance Database detected major RAMs in 63.5 % of the samples. The 
majority of mutations have HIVDRMs against EFV, NVP, FTC and 3TC, with M184V (39.7 %), K65R (30.7%) 
K103N (36.1 %) and V106M (15.4 %) mutations being the most common ones  
 
 
































































In Figure 4.10, Minor mutations were detected in 16.1%, only potential-low level (9.6%) and low-level 
resistance mutations (6.4%) of samples had IN RAMs that interfere with the efficacy of the cART.
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In this study, we investigated the HIV-1 pol PR, RT and IN regions for HIV-1 diversity and 
the prevalence of drug RAMs, from the Cape Winelands, West Coast and Overberg regions 
of the Western Cape Province of South Africa. The HIV-1 pol genome region is extremely 
valuable for researchers as it is known to harbor conserved areas needed for replication 
competence and has the regions with RAMs that interfere with the success of current cART 
regimens (De Oliveira et al., 2010). Most of the current therapeutic inhibitor drugs are 
designed targeting these regions of HIV-1 to inhibit HIV replication. HIV diversity, viral load 
monitoring and HIV drug resistance testing are important and essential tools to assess the 
success of cART. The findings of the study are discussed in this chapter. 
5.1.1. HIV-1 in rural South Africa  
There is a lack of data regarding HIV-1 diversity and the prevalence of HIV-1 RAM strains 
amongst treatment and naïve patients in remote and non-major metropolitan centers of South 
Africa, where resources, such as health clinics, are often limited. Most of the studies have 
been done in the major cities where accessibility of health care facilities by the researchers to 
collect samples is much convenience for them (Jacobs et al., 2008; Papathanasopoulos et al., 
2010; Parboosing et al., 2011). 
South Africa has the largest number (7.0 million) of HIV-1 infection worldwide with an 
estimated prevalence of 19.2 %, recorded in 2015 (UNAIDS Gap report, 2016). People who 
died from HIV-related illnesses were 180,000, 30.5% of all deaths in South Africa and 
380,000 new HIV infections (HIV&AIDS statistics, 2015). High variations of HIV/AIDS are 
observed between the provinces of South Africa. Kwazulu-Natal has the highest prevalence 
of 40.1%, while HIV prevalence in the Western Cape Province is significantly lower (18.0%) 
than the national estimates (NDOH, 2014). The sexually active age group (males and 
females, aged 15 - 49 years) represents 55.7% of the Western Cape Province population. The 
HIV prevalence amongst this age group is 9.2%. Western Cape is one of the provinces that 




showed high increases in the prevalence of HIV, from 5.0% in 2011 to 18.0% in 2014 
(NDOH, 2014). The Cape Winelands, Overberg, and West Coast regions are remote district 
areas in the Western Cape Province. In the Province the Cape Winelands accounts for 15.0% 
of people living with HIV/AIDS, followed by Overberg (13.9%) and West Coast (9.6%), 
respectively. For many of the citizens residing in these districts access to clinical resources 
are still limited and only a few patients are able to access the health care facilities, as they are 
living in areas that are far from public health care centre. 
A major primary mode of HIV transmission among this population is unprotected 
heterosexual contact (NDOH, 2011). Unemployment, lack of education, poverty, IDUs, 
alcohol abuse and sex workers are the other driving forces of HIV/AIDS epidemic in 
communities of South Africa. Despite the lowest prevalence of HIV in the Western Cape 
Province, of South Africa close monitoring and surveillance of HIV-1 is still crucial to 
control the epidemic. Many of the people from unmonitored remote areas who are living with 
HIV-1 migrate to major city Centre for employment and by doing so, the chances of HIV-1 
spread increases. It was previously suggested that the labour system forced young men to 
abandon their communities and families, and by doing so may have been the route of HIV-1 
transmission within South Africa (Hargrove, 2008; Wilkinson et al., 2015).  
5.1.2. HIV-1 diversity in South Africa 
In the early 1980s, HIV-1 subtypes B and D were responsible for the initial epidemic in 
South Africa, identified among homosexual contacts (Engelbrecht et al., 1995; Sher, 1989). 
Since the early 1990s, subtype C has been the driving force of the HIV-1 epidemic through 
heterosexual contact (van Harmelen et al., 1997). HIV-1 Subtype C is the dominant cause of 
infection in South Africa and accounts for the majority of infections, with minor subtype B 
still circulating among the high-risk group of homosexuals, as well as among the heterosexual 
population (Jacobs et al., 2009; Jacobs et al., 2014).  
In our study, we characterized the HIV-1 diversity from patients being monitored for the 
HIV-1 viral load from the Cape Winelands, West Coast and Overberg district of the Western 
Cape Province of South Africa. This was done using various HIV-1 online tools and 
phylogenetic tree analysis to validate and confirm the results obtained. Phylogenetic analysis 
of the three district sequences, Figures 4.6 - 4.8, reveals that HIV-1 subtype C (93.7%) is the 
most prevalent form in the Western Cape, with another ten non-C subtypes detected and 




confirmed by phylogenetic trees, four subtype A1 (2.9%), four subtype B (2.9%), one 
subtype D (0.25%) and one subtype H (0.25%). To the best of our understanding, this might 
be the first time HIV-1 subtype H been identified in the Western Cape Province, of South 
Africa. Two recent studies by Jacobs et al., 2014 and Wilkinson et al., 2015, showed that 
HIV-1 subtype C is still the dominant subtype circulating in South Africa, with continuous 
introduction of non-C subtypes in the Western Cape Province of South Africa. 
Other non-C subtypes have been sporadically identified (Loxton et al., 2005; Hemelaar et al., 
2012, Bredell et al., 2002; Papathanasopoulos et al., 2010; Wilkinson et al., 2015, Wilkinson 
et al., 2009; Iweriebor et al., 2011, Jacobs et al., 2009). A follow-up study conducted by 
Jacobs et al., 2014 in our laboratory identified circulating BC strains in at least 4.6% of their 
study population, followed by a more recent study in our laboratory conducted by Wilkinson 
et al., 2015 that also identified other non-C subtypes: B, A, G, URF_AD and URF_AC 
circulating in the Western Cape (Wilkinson et al., 2015). Loxton et al., 2005, from our 
laboratory identified subtype D from full four length genome sequences. As the HIV-1 
epidemic continues to increase in the country there is also a need to expand the research to 
rural communities and continue monitoring the current HIV-1 population to screen for 
circulating subtypes. 
Thus, identification of subtype B sequences among the viral load patient sequences reveals 
that this subtype is still circulating in the community and probably to the rest of South Africa 
and has most likely entered the heterosexual community as well. The majority of non-C 
subtypes identified in the study came from the Cape Wineland , with the exception of one  
sequence that identified as Subtype A1 (14_ZA_WC_WC_1_IN) that originated  from the 
West Coast (Figure 4.8). Two female patient sequences from the Ceres community of the 
Cape Winelands identified as A1 and clustered close to each other with a bootstrap support of 
99%. In addition, two more female patient’s sequences from the De Doorns community of 
Cape Winelands identified as subtype A1 and clustered close to each other, with a bootstrap 
support of 99%. A possible explanation might be that the sequences are from samples 
originating from epidemiologically linked patients that are possible related.  
As a result of diverse viral strains and the identification of other non-C subtype strains, URFs 
and CRFs within our country and worldwide, it is important to regularly monitor the diversity 
and redistribution of viral strains. HIV diversity have a potential effects in clinical diagnosis, 
vaccine development, treatment and prevention (Peeters et al., 2000; Lal et al., 2005). 




Although genetic diversity of HIV-1 in South Africa has documented in several regions of 
South Africa (Gordon et al., 2003; Hemelaar et al., 2006; Bredell et al., 1998; Pillay et al., 
2002), it is important to address the data regarding the development of drug resistance and 
HIV-1 diversity through periodic studies.  
5.1.3. HIV-1 diagnostic in South Africa 
VLs testing, as performed in our laboratory are used to monitor the treatment response and 
adherence problems early before the emergence of resistance. A subset of the patient with a 
detectable level of VL (>1000 copies/ml) after 3 months of initiation of therapy despite 100% 
adherence, additional adherence interventions is implemented and a repeat of VLs monitoring 
is done in 2-3 months (Hirsch et al., 2008). After 2-3 months of monitoring and the VLs 
remains above (>1000 copies/ml) such patients are referred for a drug resistance testing to 
identify and characterize drug resistance mutations and if the patients meet the criteria of 
switching the regimens, resistance will be a key to guide on the selection of new therapy 
regimen. During drug resistance testing, patient sequence are further used for the analysis of 
the HIV-1 diversity. HIV-1 diversity among subtypes it was reported to have a possible effect 
in yielding differential patterns of RAMs that interfere with the success of treatment (Ross et 
al., 2010) and associated with other clinical consequences such as escape of selected variants 
(Fischer et al., 2010) and progression of the disease (Lemey et al., 2007; Salemi et al., 2001). 
New developed sequencing methods are focused on capturing low-frequency sequencing 
variants for characterization of intrahost diversity (Vrancken et al., 2010). 
5.1.4. cART and the prevalence of drug RAMs 
South Africa is the region most heavily affected by HIV/AIDS worldwide (UNAIDS gap 
report, 2016). Since the initiation of country wide cART in the country in April 2004, the 
HIV-1 infected population had benefited greatly from the cART program by reducing the 
mortality and morbidity rate in the country. South Africa has the largest antiretroviral 
program in the world with 3.4 million people on cART, this accounts for 48% of adults on 
cART (UNAIDS Gap Report, 2016). After the scale-up of cART in 2012, the mortality rate 
among children was reduced by 20% (HRSC, 2014). In the resource-limited settings of the 
Western Cape Province, the cART program was implemented as early as 2001, followed only 
in 2004 by the rest of the country (WHO, 2014). The margin of long-term cART success can 
be interrupted by the development of HIV-1 drug RAMs. The emergence of HIV-1 RAMs 
has been raised as the potential threat to the success of the cART worldwide (Bertagnolio et 




al., 2013; Hamers et al., 2012). HIV-1 drug resistance testing is a useful tool for clinical care, 
such as the choice of active regimens before the patient’s initiate therapy and also to help 
identify the presence of RAMs in patients prior to initiation of therapy. Resistance testing can 
be used to monitor the patients who are already on cART. HIV  
The 205 HIV-1 positive patient samples selected for this study form part of a larger 
diagnostic monitoring viral load program in the Western Cape. All the patients receiving 
HIV-1 VLs are presumed on cART, as the Western Cape Consolidated Guidelines for HIV 
treatment recommend VLs monitoring only to patients who were on therapy for three months. 
However, only 58/205 (28.3%) of our study patients clearly indicated treatment regimens on 
patient data forms. Thus, we cannot confidently say if the patients were receiving cART, if at 
all. A high viral load assumes that cART is not being implemented properly, either through 
low adherence or suboptimal therapy that lead to viral resistance (Paredes et al., 2010). Our 
laboratory has previously developed an in-house HIV-1 resistance assay; however, these tests 
are not routinely done and only done on request (Claassen et al, personal communication – 
article in preparation). 
In our, study we detected HIV-1 RT drug RAMs in 61.7% of the analyzed samples No major 
PI and IN mutations were detected. Of the pol RT sequences analysed seventy-one (61.7%) 
had major RTI RAMs, Table 4.6-4.7 and Figure 4.9 shows the results for RT, PR and IN 
analyzed. M184I/V causes high-level resistance to lamivudine (3TC) and emtricitabine (FTC) 
and low-level resistance to ddI and ABC. V106M is a nonpolymorphic mutation that causes 
high-level resistance to NVP and EFV while K65R causes intermediate/high-level resistance 
to TDF, ddI, ABC and d4T and low to intermediate-level resistance to 3TC and FTC. K65R 
increases susceptibility to AZT. However the detection of high level of K65R mutation in our 
study population might be attributed by more rapid in vivo selection of the K65R mutation in 
subtype C virus (Brenner BG et al., 2006). Thus far, in South Africa only few studies have 
investigated the antiretroviral RAMs in patients treated with TDF. One study by Sunpath et al 
2012.showed that more than 65% of the patients on the TDF developed the K65R RAMs, 
whereas the second study found that K65R mutation was more prevalent in 46 % of the 
patients (Van Zyl et al., 2013). A third study which is substantially lower compared to the 
other two studies showed a K65R prevalence of 23% (Hoffman et al., 2013).A particular 
concern is that K65R RAMs has been found to cause cross-resistance mutations against most 
of the NRTIs (Johnson et al., 2011) and therefore interfere with the effectiveness of the 




second line regimens.K103N causes high-level resistance to nevirapine (NVP) and efavirenz 
(EFV).  
In addition detection of low-level RAMS to PR inhibitors and INSTIs in our study illustrates 
a possible threat to the future long-term management of HIV in South Africa contexts. The 
absence of major drug RAMs against Raltegravir have been documented in the recent studies 
conducted in South Africa (Gauteng) and in the other parts of the world. For example, 
Besong and Nwobegay, (Besong and Nwobegahay, 2013) observed minor RAMs and 
polymorphism in 7% of the sequences analysed. Fish et al. ( Fish et al., 2010) detected 
polymorphism from 73 sequences obtained from South African HIV-1 infected patients. 
Similar results were also documented in Mozambique (Oliveira et al., 2012). In a previous 
study conducted in our laboratory, where 140 naïve -treated patients samples were received 
from 14 different clinics from the Cape Metropole area of South Africa during the period of 
2002 to 2004 before the large scale increase of access to cART in the Western Cape, the 
prevalence of drug resistance mutations in the treatment naïve population was <5% (Jacobs et 
al., 2009). In another study in Cape Town, Western Cape the prevalence of major drug 
resistance mutations in naïve patients was 2.5% (Orrell et al., 2009) and in children born of 
drug-experienced mothers (Van Zyl et al., 2010). Our current study shows a prevalence of 
RAMs from small population size of three districts around the western Cape province of 
south Africa ,this indicate that the more the population size and expansion in samples 
collection from different regions within the country, true prevalence and reliability of results 
will be relied upon, because our results shows us not to ignore the resistance testing of HIV 
population from disadvantaged settings, since most of the studies are done in the large urban 
centres areas, where researchers have access to clinics and patient samples. 
5.1.5. Strength of the study  
The work describes the first data of HIV-1 diversity and RAMs of the VL sample sequences 
from three remote areas of the Western Cape Province of South Africa. In our laboratory, we 
have access to patient’s VLs samples for further monitoring of cART outcome and 
characterization of HIV-1 for diversity using modern molecular techniques and analysis. We 
were able to identify the presence of other non-C subtypes causing infection in the Western 
Cape remote areas. With our analyses, we found a high prevalence of RTIs, despite having 
limited therapy treatment data for these patients we further included analysis of the IN 
genome region and we detected low-level RAMs against IN inhibitors drugs (DTG, EVG and 




RAL) before third line therapy in South Africa. Thus, we already have optimized protocol for 
IN genotyping. Third line therapy treatment is not yet available in the low-resource setting 
and only available in high-income countries or through the private health sector. Therefore, 
our IN results give us insights and advantages knowledge of what to expect with regards to 
the emergence of RAMs in future when third line therapy is introduced in our country. This is 
a unique, important and valuable study as it bridges the lack of data regarding the emergence 
of RAMs and the increasing number of non-C subtypes in the remote areas of the Western 
Cape Province.  
5.1.6. Limitations  
A major limitation of this study is the lack of HIV-1 resistance data information available for 
all of the patients. In many cases the viral load request forms were filled incomplete, thus we 
could not make informative conclusions about RAMs and treatment outcomes. Due to ethical, 
reasons we could also not relay the findings of the study directly back to the patients or 
clinicians. However, the findings and recommendations from this study will be summarized 
for peer review publication. Due to time constraints and the high cost of laboratory 
techniques and lack of funding, we couldn’t add more samples and district to the study and 
we could not as yet include patient follow-up the patients for additional samples. Another 
limitation was the fact that DNA amplification and sequencing was not successful in about 
30% of the samples. This is most likely due to the high sequence variability seen in HIV, thus 
primer mismatches lead to inefficient PCR amplification and DNA sequencing.  
 
5.1.7. Prospective work and recommendations 
In future, we will include the use of Next Generation Sequencing (NGS) technology to help 
characterize our HIV strains. NGS could be especially useful to study non-Cs, CRFs and 
URFs in South Africa. NGS can also potentially be used for diagnostic HIV-1 resistance 
testing as being done in many first world laboratories already. NGS has been shown to detect 
minority variants that might be of potential clinical significant to hamper the success of the 
ARV treatment. In addition, resistance testing should be recommended before the initiation of 
therapy and to those who are already failing therapy.  
 





With the continuous identification of non-C HIV-1 subtypes and drug RAMs in the country, 
there is a need to evaluate the effect of subtype diversity s on the success of cART. Studies 
have previously suggested that HIVDRM might be subtypes specific in certain cases. 
Optimally, a baseline resistance test should be performed for each patient before cART is 
initiated to ensure the chances of successful and complete virological suppression of HIV-1. 
This remains logistically challenging for the South African environment with so many people 
infected with HIV/AIDS. A resistance test should be available for patients failing therapy and 
we should continue to monitor the influence of RAMs and the diversity of subtypes on the 
HIV-1 epidemic in the rest of the country. It is important to understand the relation between 
the HIVDRM and geographic diversity of the epidemic. 
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APPENDIX B: HIV-1 viral load cohort regimens 
SAMPLE CODE REGIMEN SAMPLE CODE REGIMEN 
11_ZA_WC_CW_35 TDF+3TC+EFV 14_ZA_WC_OV_13 D4T+3TC+KLT 
11_ZA_WC_CW_38 TDF+3TC+EFV 14_ZA_WC_OV_8 TDF+EFV+FTC 
11_ZA_WC_CW_39 TDF+EFV+FTC 14_ZA_WC_WC_12 TDF+3TC+EFV 
11_ZA_WC_CW_4 TDF+3TC+LPV/r 14_ZA_WC_CW_46 NEW 
11_ZA_WC_CW_40 TDF+3TC+EFV 14_ZA_WC_CW_46 NEW 
11_ZA_WC_CW_41 LPV +Truvada 14_ZA_WC_CW_48 TDF+3TC+EFV 
11_ZA_WC_CW_42 TDF+3TC+LPV/r 14_ZA_WC_CW_49 TDF+3TC+LPV/r 
11_ZA_WC_CW_7 TDF+3TC+EFV 14_ZA_WC_CW_51 FDC 
11_ZA_WC_WC_23 TDF+EFV+FTC 14_ZA_WC_CW_56 NEW 
11_ZA_WC_WC_5 FDC 14_ZA_WC_OV_10 TDF+3TC+EFV 
11_ZA_WC_WC_6 TDF+3TC+EFV 14_ZA_WC_OV_17 TDF+3TC+EFV 
11_ZA_WC_WC_8 TDF+3TC+EFV 14_ZA_WC_OV_20 TDF+3TC+KLT 
12_ZA_WC_CW_24 TDF+EFV+FTC 14_ZA_WC_OV_6 FDC 
12_ZA_WC_CW_44 TDF+3TC+EFV 14_ZA_WC_OV_7 TDF+EFV+FTC 
12_ZA_WC_CW_46 TDF+3TC+EFV 14_ZA_WC_OV_8 TDF+3TC+EFV 
12_ZA_WC_CW_47 D4T+3TC+NVP 14_ZA_WC_OV_9 TDF+3TC+EFV 
12_ZA_WC_CW_48 NEW 14_ZA_WC_WC_11 TDF+EFV+FTC 
12_ZA_WC_CW_49 AZT +3TC+EFV+RIF 14_ZA_WC_WC_13 ABC +TDF +3TC 
12_ZA_WC_CW_5 TDF+3TC+EFV 14_ZA_WC_WC_16 TDF+EFV+FTC 
12_ZA_WC_CW_50 AZT +3TC+KLT +RTF 14_ZA_WC_WC_20 ABC+3TC+EFV 
12_ZA_WC_CW_51 AZT+3TC+NVP 15_ZA_WC_CW_15 D4T+3TC+EFV 
12_ZA_WC_CW_53 TDF+3TC+EFV 15_ZA_WC_CW_16 TDF+EFV+FTC 
12_ZA_WC_CW_54 TDF+3TC+EFV 15_ZA_WC_CW_17 NEW 
12_ZA_WC_CW_55 ABC +TDF +EFV 15_ZA_WC_CW_18 AZT +3TC+EFV 
12_ZA_WC_CW_56 TDF+EFV+FTC 15_ZA_WC_CW_19 TDF+3TC+EFV 
12_ZA_WC_CW_57 TDF+3TC+EFV 15_ZA_WC_CW_21 EFV+LAMIVUDINE 
13_ZA_WC_CW_66 TDF+3TC+EFV 15_ZA_WC_CW_22 TDF+EFV+FTZ 
13_ZA_WC_CW_67 TDF+3TC+KLT+INH 15_ZA_WC_CW_23 TDF+3TC+EFV 
13_ZA_WC_CW_68 TDF+3TC+EFV 15_ZA_WC_CW_32 AZT +3TC+NVP 
13_ZA_WC_CW_69 D4T+3TC+KLT 15_ZA_WC_CW_33 TDF+3TC+EFV 









APPENDIX C: HIV-1 viral load results 
Appendix A.RNA Viral loads results using the Abbott LCx® HIV Quantitative assay  
Sample Code Age Gender Viral loads (RNA 
Copies per/ml) 
Sample Date 
11_ZA_WC_CW_3 39 M 4888 2011 
11_ZA_WC_CW_34 36 F 82883 2011 
11_ZA_WC_CW_35 26 F 36148 2011 
11_ZA_WC_CW_38 37 M 7874 2011 
11_ZA_WC_CW_39 52 F 255538 2011 
11_ZA_WC_CW_4 15 F 303100 2011 
11_ZA_WC_CW_40 49 F 43580 2011 
11_ZA_WC_CW_41 41 M 13587 2011 
11_ZA_WC_CW_42 27 F 25720 2011 
11_ZA_WC_CW_7 50 M 815609 2011 
11_ZA_WC_CW_8 27 F 35767 2011 
11_ZA_WC_CW_9 28 F 11980 2011 
11_ZA_WC_OV_1 31 F 6235 2011 
11_ZA_WC_OV_15 11 F 78887 2011 
11_ZA_WC_OV_17 57 F 254353 2011 
11_ZA_WC_OV_18 13 M 8954 2011 
11_ZA_WC_OV_3 25 M 437261 2011 
11_ZA_WC_WC_1 29 F 6795 2011 
11_ZA_WC_WC_14 50 F 6715 2011 
11_ZA_WC_WC_15 50 F 97740 2011 
11_ZA_WC_WC_16 26 M 198439 2011 
11_ZA_WC_WC_17 35 F 8205 2011 
11_ZA_WC_WC_2 31 F 21854 2011 
11_ZA_WC_WC_20 35 F 470985 2011 
11_ZA_WC_WC_3 47 F 436327 2011 
11_ZA_WC_WC_4 20 F 8095 2011 
11_ZA_WC_WC_5 27 M 548203 2011 
11_ZA_WC_CW_1 24 F 7736 2011 
11_ZA_WC_CW_17 26 F 7191 2011 
11_ZA_WC_CW_25 27 F 660756 2011 
11_ZA_WC_CW_27 39 M 5758 2011 
11_ZA_WC_CW_3 34 M 286717 2011 
11_ZA_WC_CW_4 31 F 3532 2011 
11_ZA_WC_CW_6 35 M 588250 2011 
11_ZA_WC_CW_64 36 M 51839 2011 
11_ZA_WC_CW_7 26 F 3421 2011 
11_ZA_WC_OV_19 57 F 4556 2011 
11_ZA_WC_WC_8 25 M 148810 2011 
11_ZA_WC_WC_2 26 M 55634 2011 
11_ZA_WC_WC_33 35 F 4317 2011 




Sample Code Age Gender Viral loads (RNA 
Copies per/ml) 
Sample Date 
11_ZA_WC_OV_2 13 M 44065 2011 
11_ZA_WC_OV_23 11 M 368492 2011 
11_ZA_WC_WC_1 39 F 2173 2011 
11_ZA_WC_WC_17 50 M 164867 2011 
11_ZA_WC_WC_23 50 M 3994 2011 
11_ZA_WC_WC_5 25 M 125810 2011 
11_ZA_WC_WC_6 26 M 9334 2011 
11_ZA_WC_WC_8 35 F 439818 2011 
12_ZA_WC_CW_24 42 F 619718 2012 
12_ZA_WC_CW_37 26 M 293993 2012 
12_ZA_WC_CW_43 21 F 6766 2012 
12_ZA_WC_CW_44 38 F 3137 2012 
12_ZA_WC_CW_46 30 F 7081 2012 
12_ZA_WC_CW_47 30 M 2909 2012 
12_ZA_WC_CW_48 30 F 25698 2012 
12_ZA_WC_CW_49 35 M 13415 2012 
12_ZA_WC_CW_5 16 M 360840 2012 
12_ZA_WC_CW_50 38 F 2528632 2012 
12_ZA_WC_CW_51 32 F 983658 2012 
12_ZA_WC_CW_53 32 M 2096 2012 
12_ZA_WC_CW_54 43 F 17612 2012 
12_ZA_WC_CW_55 13 F 56130 2012 
12_ZA_WC_CW_56 52 F 69283 2012 
12_ZA_WC_CW_57 32 F 116542 2012 
12_ZA_WC_CW_58 36 F 4278 2012 
12_ZA_WC_CW_59 46 F 9515 2012 
12_ZA_WC_CW_6 54 F 44992 2012 
12_ZA_WC_CW_60 26 F 23430 2012 
12_ZA_WC_OV_16 38 M 37297 2012 
12_ZA_WC_OV_19 36 F 19059 2012 
12_ZA_WC_OV_20 33 M 3546 2012 
12_ZA_WC_WC_10 45 F 20499 2012 
12_ZA_WC_WC_18 31 F 11124 2012 
12_ZA_WC_WC_21 29 F 1240706 2012 
12_ZA_WC_WC_22 43 M 2416 2012 
12_ZA_WC_CW_10 32 F 146528 2012 









Sample Code Age Gender Viral loads (RNA 
Copies per/ml) 
Sample Date 
12_ZA_WC_CW_13 24 M 2061393 2012 
12_ZA_WC_CW_15 21 F 45884 2012 
12_ZA_WC_CW_16 42 M 1309767 2012 
12_ZA_WC_CW_18 36 M 366761 2012 
12_ZA_WC_CW_20 29 F 320249 2012 
12_ZA_WC_CW_22 26 F 29191 2012 
12_ZA_WC_CW_23 32 M 2562 2012 
12_ZA_WC_CW_24 23 F 89525 2012 
12_ZA_WC_CW_37 36 F 22525 2012 
12_ZA_WC_CW_38 46 F 6214 2012 
12_ZA_WC_CW_39 33 M 36233 2012 
12_ZA_WC_CW_40 40 F 590722 2012 
12_ZA_WC_CW_41 26 M 882499 2012 
12_ZA_WC_CW_42 38 F 221054 2012 
12_ZA_WC_CW_44 46 M 603027 2012 
12_ZA_WC_CW_9 34 F 14564 2012 
12_ZA_WC_OV_13 33 F 12706 2012 
12_ZA_WC_OV_3 36 M 3873 2012 
12_ZA_WC_OV_4 28 M 2172905 2012 
12_ZA_WC_OV_5 34 M 52992 2012 
12_ZA_WC_WC_10 30 F 537448 2012 
12_ZA_WC_WC_12 31 M 122971 2012 
12_ZA_WC_WC_14 29 F 3272216 2012 
12_ZA_WC_WC_15 30 F 14499 2012 
12_ZA_WC_WC_2 40 M 225889 2012 
12_ZA_WC_WC_9 9 F 47360 2012 
13_ZA_WC_CW_1 35 F 2329 2013 
13_ZA_WC_CW_2 42 F 7232 2013 
13_ZA_WC_CW_28 30 M 2292 2013 
13_ZA_WC_CW_31 33 M 9136 2013 
13_ZA_WC_CW_45 25 F 11675 2013 
13_ZA_WC_CW_52 49 M 211680 2013 
13_ZA_WC_CW_61 43 M 228696 2013 
13_ZA_WC_CW_62 29 M 12618 2013 
13_ZA_WC_CW_63 52 F 14623 2013 
13_ZA_WC_CW_64 39 M 775585 2013 









Sample Code Age Gender Viral loads (RNA 
Copies per/ml) 
Sample Date 
13_ZA_WC_CW_66 14 M 205860 2013 
13_ZA_WC_CW_67 40 F 104991 2013 
13_ZA_WC_CW_68 28 M 48548 2013 
13_ZA_WC_CW_69 42 M 28843 2013 
13_ZA_WC_OV_10 59 F 26389 2013 
13_ZA_WC_OV_14 42 F 4660 2013 
13_ZA_WC_OV_2 46 F 152537 2013 
13_ZA_WC_OV_22 30 F 246511 2013 
13_ZA_WC_OV_9 14 M 3862 2013 
13_ZA_WC_WC_19 35 F 2350 2013 
13_ZA_WC_WC_23 28 F 136932 2013 
13_ZA_WC_CW_2 52 F 14945 2013 
13_ZA_WC_CW_26 21 F 20162 2013 
13_ZA_WC_CW_29 42 F 25684 2013 
13_ZA_WC_CW_30 28 M 170852 2013 
13_ZA_WC_CW_31 32 F 27760 2013 
13_ZA_WC_CW_32 33 M 288729 2013 
13_ZA_WC_CW_36 42 F 3397 2013 
13_ZA_WC_CW_47 49 F 18073 2013 
13_ZA_WC_CW_5 49 F 20499 2013 
13_ZA_WC_CW_50 35 M 61674 2013 
13_ZA_WC_CW_52 21 M 121276 2013 
13_ZA_WC_CW_8 39 F 21637 2013 
13_ZA_WC_OV_1 45 F 12897 2013 
13_ZA_WC_OV_11 14 F 6992 2013 
13_ZA_WC_OV_12 30 F 61739 2013 
13_ZA_WC_OV_14 59 F 7892 2013 
13_ZA_WC_OV_16 30 M 158229 2013 
13_ZA_WC_OV_18 34 M 84975 2013 
13_ZA_WC_OV_21 30 F 70893 2013 
13_ZA_WC_WC_18 36 M 4131 2013 
13_ZA_WC_WC_22 35 M 20238 2013 
13_ZA_WC_WC_3 20 M 3394 2013 
13_ZA_WC_WC_7 47 M 75033 2013 
14_ZA_WC_CW_20 20 M 4944 2014 
14_ZA_WC_CW_25 42 M 217243 2014 
14_ZA_WC_CW_26 22 M 9428 2014 








Sample Code Age Gender Viral loads (RNA 
Copies per/ml) 
Sample Date 
14_ZA_WC_CW_29 37 M 2719 2014 
14_ZA_WC_CW_30 6 F 35521 2014 
14_ZA_WC_CW_70 49 F 19411 2014 
14_ZA_WC_CW_71 32 F 45424 2014 
14_ZA_WC_OV_11 32 F 3709 2014 
14_ZA_WC_OV_12 25 M 5885 2014 
14_ZA_WC_OV_13 39 M 344660 2014 
14_ZA_WC_OV_21 14 F 14724 2014 
14_ZA_WC_OV_7 29 F 3998 2014 
14_ZA_WC_OV_8 22 F 201623 2014 
14_ZA_WC_WC_11 37 F 53996 2014 
14_ZA_WC_WC_12 43 M 538507 2014 
14_ZA_WC_WC_13 31 F 164909 2014 
14_ZA_WC_CW_28 42 M 19547 2014 
14_ZA_WC_CW_33 28 M 58138 2014 
14_ZA_WC_CW_35 6 F 705296 2014 
14_ZA_WC_CW_43 49 M 103648 2014 
14_ZA_WC_CW_45 32 F 8610 2014 
14_ZA_WC_CW_46 30 M 95949 2014 
14_ZA_WC_CW_48 22 M 5588 2014 
14_ZA_WC_CW_49 32 F 301227 2014 
14_ZA_WC_CW_51 37 F 4155 2014 
14_ZA_WC_CW_56 43 F 12618 2014 
14_ZA_WC_OV_10 22 M 70224 2014 
14_ZA_WC_OV_17 14 F 15663 2014 
14_ZA_WC_OV_20 41 F 92031 2014 
14_ZA_WC_OV_6 39 F 2035 2014 
14_ZA_WC_OV_7 36 M 166011 2014 
14_ZA_WC_OV_8 39 F 5812 2014 
14_ZA_WC_OV_9 32 F 31569 2014 
14_ZA_WC_WC_11 39 F 12571 2014 
14_ZA_WC_WC_13 34 M 45941 2014 
14_ZA_WC_WC_16 31 M 45941 2014 
14_ZA_WC_WC_20 52 M 11624 2014 
15_ZA_WC_CW_10 31 F 14441 2015 










Sample Code Age Gender Viral loads (RNA 
Copies per/ml) 
Sample Date 
15_ZA_WC_CW_12 32 F 396299 2015 
15_ZA_WC_CW_13 40 F 1328754 2015 
15_ZA_WC_CW_14 24 M 3249561 2015 
15_ZA_WC_CW_15 43 M 147609 2015 
15_ZA_WC_CW_16 43 F 608665 2015 
15_ZA_WC_CW_17 25 F 16138 2015 
15_ZA_WC_CW_18 41 M 20097 2015 
15_ZA_WC_CW_19 52 F 9709 2015 
15_ZA_WC_CW_21 26 M 7219 2015 
15_ZA_WC_CW_22 34 F 3706 2015 
15_ZA_WC_CW_23 41 F 15875 2015 
15_ZA_WC_CW_32 14 M 492505 2015 
15_ZA_WC_CW_33 22 M 150341 2015 
15_ZA_WC_CW_36 36 F 46309 2015 
15_ZA_WC_OV_4 25 F 16580 2015 
15_ZA_WC_OV_5 41 F 206291 2015 
15_ZA_WC_OV_6 32 M 541438 2015 
15_ZA_WC_WC_6 41 F 7232 2015 
15_ZA_WC_WC_7 42 F 3661 2015 
15_ZA_WC_WC_8 44 F 138983 2015 


















APPENDIX D: Nucleic acids concentration determination. 
Sample Code ng/ul 260/280  
11_ZA_WC_CW_3 124.2 1.83 
11_ZA_WC_CW_34 123.84 1.87 
11_ZA_WC_CW_35 87.08 1.82 
11_ZA_WC_CW_38 87.03 1.8 
11_ZA_WC_CW_39 83.86 1.29 
11_ZA_WC_CW_4 84.38 2.31 
11_ZA_WC_CW_40 129.01 1.81 
11_ZA_WC_CW_41 126.81 1.81 
11_ZA_WC_CW_42 100.17 1.82 
11_ZA_WC_CW_7 93.88 1.81 
11_ZA_WC_CW_8 83.93 1.84 
11_ZA_WC_CW_9 85.36 1.85 
11_ZA_WC_OV_1 136.27 1.87 
11_ZA_WC_OV_15 144.88 1.88 
11_ZA_WC_OV_17 116.37 1.88 
11_ZA_WC_OV_18 128.1 1.82 
11_ZA_WC_OV_3 136.42 1.81 
11_ZA_WC_WC_1 137.55 1.91 
11_ZA_WC_WC_14 138.98 1.89 
11_ZA_WC_WC_15 140.25 1.87 
11_ZA_WC_WC_16 106.13 1.99 
11_ZA_WC_WC_17 105.63 1.85 
11_ZA_WC_WC_2 131.32 1.93 
11_ZA_WC_WC_20 84.67 1.99 
11_ZA_WC_WC_3 84.29 1.88 
11_ZA_WC_WC_4 94.76 1.82 
11_ZA_WC_WC_5 92.99 1.85 
11_ZA_WC_CW_1 105.1 1.85 
11_ZA_WC_CW_17 104.12 1.85 
11_ZA_WC_CW_25 103.5 1.81 
11_ZA_WC_CW_27 102.21 1.83 
11_ZA_WC_CW_3 122.36 1.83 
11_ZA_WC_CW_4 122.85 1.85 
11_ZA_WC_CW_6 100.19 1.81 
11_ZA_WC_CW_64 99.72 1.86 
11_ZA_WC_CW_7 116.01 1.84 








Sample Code ng/ul 260/280  
11_ZA_WC_OV_2 94.45 1.89 
11_ZA_WC_OV_23 94.59 1.82 
11_ZA_WC_WC_1 105.59 1.87 
11_ZA_WC_WC_17 103 1.85 
11_ZA_WC_WC_23 120.28 1.84 
11_ZA_WC_WC_5 120.65 1.88 
11_ZA_WC_WC_6 100.48 1.91 
11_ZA_WC_WC_8 103.16 1.86 
12_ZA_WC_CW_24 121.11 1.83 
12_ZA_WC_CW_37 120.9 1.85 
12_ZA_WC_CW_43 80.98 2.15 
12_ZA_WC_CW_44 80.51 2.19 
12_ZA_WC_CW_46 128.79 1.82 
12_ZA_WC_CW_47 125.05 1.83 
12_ZA_WC_CW_48 121.4 1.83 
12_ZA_WC_CW_49 123.42 1.86 
12_ZA_WC_CW_5 89.1 1.83 
12_ZA_WC_CW_50 79.27 1.83 
12_ZA_WC_CW_51 86.18 1.61 
12_ZA_WC_CW_53 86.91 1.63 
12_ZA_WC_CW_54 109.92 1.86 
12_ZA_WC_CW_55 110.41 1.9 
12_ZA_WC_CW_56 40.56 1.88 
12_ZA_WC_CW_57 85.1 1.92 
12_ZA_WC_CW_58 89.96 1.9 
12_ZA_WC_CW_59 32.82 1.95 
12_ZA_WC_CW_6 106.24 1.82 
12_ZA_WC_CW_60 106.63 1.82 
12_ZA_WC_OV_16 106.45 1.82 
12_ZA_WC_OV_19 101.58 1.8 
12_ZA_WC_OV_20 106.41 1.82 
12_ZA_WC_WC_10 105.14 1.86 
12_ZA_WC_WC_18 112.31 1.84 
12_ZA_WC_WC_21 111.11 1.87 
12_ZA_WC_WC_22 82.52 1.92 
12_ZA_WC_CW_10 81 1.91 









Sample Code ng/ul 260/280  
12_ZA_WC_CW_13 65.64 1.87 
12_ZA_WC_CW_15 97.6 2.16 
12_ZA_WC_CW_16 96.02 2.12 
12_ZA_WC_CW_18 107.87 1.79 
12_ZA_WC_CW_20 108.41 1.83 
12_ZA_WC_CW_22 117.72 1.84 
12_ZA_WC_CW_23 120.54 1.83 
12_ZA_WC_CW_24 96.3  1.88  
12_ZA_WC_CW_37 119.56 1.86 
12_ZA_WC_CW_38 110.77 1.87 
12_ZA_WC_CW_39 94.59 1.85 
12_ZA_WC_CW_40 94.46 1.87 
12_ZA_WC_CW_41 141.09 1.88 
12_ZA_WC_CW_42 140.13 1.88 
12_ZA_WC_CW_44 121.96 1.82 
12_ZA_WC_CW_9 121.3 1.87 
12_ZA_WC_OV_13 62.09 1.82 
12_ZA_WC_OV_3 63.03 1.81 
12_ZA_WC_OV_4 94.48 2.21 
12_ZA_WC_OV_5 94.18 2.15 
12_ZA_WC_WC_10 115.45 1.86 
12_ZA_WC_WC_12 115.53 1.85 
12_ZA_WC_WC_14 85.9 1.84 
12_ZA_WC_WC_15 85.03 1.83 
12_ZA_WC_WC_2 47.67 1.99 
12_ZA_WC_WC_9 57.75 1.93 
13_ZA_WC_CW_1 90.6 1.81 
13_ZA_WC_CW_2 91.35 1.79 
13_ZA_WC_CW_28 115.16 1.86 
13_ZA_WC_CW_31 117.15 1.83 
13_ZA_WC_CW_45 92.89 1.87 
13_ZA_WC_CW_52 91.74 1.8 
13_ZA_WC_CW_61 110.34 1.82 
13_ZA_WC_CW_62 109.15 1.87 
13_ZA_WC_CW_63 293.75 1.83 
13_ZA_WC_CW_64 85.08 1.83 









Sample Code ng/ul 260/280  
13_ZA_WC_CW_66 78.36 2.15 
13_ZA_WC_CW_67 80.09 2.21 
13_ZA_WC_CW_68 101.15 2.19 
13_ZA_WC_CW_69 101.85 2.24 
13_ZA_WC_OV_10 82.13 2.21 
13_ZA_WC_OV_14 77.71 2.22 
13_ZA_WC_OV_2 77.24 1.82 
13_ZA_WC_OV_22 79.06 1.73 
13_ZA_WC_OV_9 113.59 1.85 
13_ZA_WC_WC_19 112.95 1.87 
13_ZA_WC_WC_23 91.9 1.86 
13_ZA_WC_CW_2 92.1 1.86 
13_ZA_WC_CW_26 127.1 1.85 
13_ZA_WC_CW_29 129.36 1.84 
13_ZA_WC_CW_30 99.43 1.89 
13_ZA_WC_CW_31 100.25 1.84 
13_ZA_WC_CW_32 78.85 1.8 
13_ZA_WC_CW_36 78.67 1.79 
13_ZA_WC_CW_47 107.61 1.87 
13_ZA_WC_CW_5 107.85 1.81 
13_ZA_WC_CW_50 117.18 1.79 
13_ZA_WC_CW_52 115.48 1.87 
13_ZA_WC_CW_8 117.79 1.85 
13_ZA_WC_OV_1 81.86 2.21 
13_ZA_WC_OV_11 82.17 2.1 
13_ZA_WC_OV_12 112.13 1.85 
13_ZA_WC_OV_14 124.79 1.83 
13_ZA_WC_OV_16 90.98 1.82 
13_ZA_WC_OV_18 88.57 1.77 
13_ZA_WC_OV_21 91.85 1.86 
13_ZA_WC_WC_18 92.39 1.81 
13_ZA_WC_WC_22 90.93 1.76 
13_ZA_WC_WC_3 89.03 1.83 
13_ZA_WC_WC_7 76.97 1.77 
14_ZA_WC_CW_20 76.24 1.79 
14_ZA_WC_CW_25 118.99 1.87 









Sample Code ng/ul 260/280  
14_ZA_WC_CW_29 117.4 1.83 
14_ZA_WC_CW_30 113.9 1.83 
14_ZA_WC_CW_70 105.41 1.83 
14_ZA_WC_CW_71 106.82 1.85 
14_ZA_WC_OV_11 101.64 1.8 
14_ZA_WC_OV_12 69.98 1.81 
14_ZA_WC_OV_13 70.28 1.84 
14_ZA_WC_OV_21 129.64 1.85 
14_ZA_WC_OV_7 110.11 1.85 
14_ZA_WC_OV_8 116.94 1.85 
14_ZA_WC_WC_11 124.02 1.83 
14_ZA_WC_WC_12 97.81 2.14 
14_ZA_WC_WC_13 98.29 2.2 
14_ZA_WC_CW_28 86.88 1.86 
14_ZA_WC_CW_33 89.52 1.85 
14_ZA_WC_CW_35 124.69 1.86 
14_ZA_WC_CW_43 123.77 1.86 
14_ZA_WC_CW_45 124.74 1.89 
14_ZA_WC_CW_46 126.99 1.86 
14_ZA_WC_CW_48 121.1 1.86 
14_ZA_WC_CW_49 129.8 1.87 
14_ZA_WC_CW_51 88.47 1.83 
14_ZA_WC_CW_56 89.28 1.83 
14_ZA_WC_OV_10 73.12 1.82 
14_ZA_WC_OV_17 74.52 1.82 
14_ZA_WC_OV_20 97.79 2.18 
14_ZA_WC_OV_6 99.67 2.19 
14_ZA_WC_OV_7 99.83 1.91 
14_ZA_WC_OV_8 101.14 1.91 
14_ZA_WC_OV_9 54.94 1.89 
14_ZA_WC_WC_11 44.99 1.89 
14_ZA_WC_WC_13 121.51 1.83 
14_ZA_WC_WC_16 120.66 1.86 
14_ZA_WC_WC_20 109.39 1.82 
15_ZA_WC_CW_10 110.44 1.86 









Sample Code ng/ul 260/280  
15_ZA_WC_CW_12 72.5 1.89 
15_ZA_WC_CW_13 72.57 1.9 
15_ZA_WC_CW_14 98.98 1.85 
15_ZA_WC_CW_15 98.26 1.87 
15_ZA_WC_CW_16 117.78 1.89 
15_ZA_WC_CW_17 116.9 1.88 
15_ZA_WC_CW_18 84.45 1.83 
15_ZA_WC_CW_19 84.15 1.81 
15_ZA_WC_CW_21 101.08 1.84 
15_ZA_WC_CW_22 165.3 1.47 
15_ZA_WC_CW_23 102.86 1.82 
15_ZA_WC_CW_32 114.85 1.85 
15_ZA_WC_CW_33 111.04 1.85 
15_ZA_WC_CW_36 76.91 1.82 
15_ZA_WC_OV_4 76.82 1.82 
15_ZA_WC_OV_5 101.08 1.84 
15_ZA_WC_OV_6 100.04 1.85 
15_ZA_WC_WC_6 117.89 1.85 
15_ZA_WC_WC_7 117.82 1.86 
15_ZA_WC_WC_8 88.38 1.83 
15_ZA_WC_WC_9 88.88 1.82 
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